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Cardiac surgery and blood transfusion
In the Netherlands, sixteen hospitals, including eight university hospitals, perform cardiac surgery 
on a daily basis. In the last 20 years, over 200.000 cardiac surgeries have been performed and 
the number of procedures keeps increasing every year.1 For example, in 2006, 14.013 open 
cardiac procedures were performed in the Netherlands whereas in 2015 this number was 16.346 
in a population of 17 million people.2 This rise in numbers can be explained by the higher life 
expectancy, less invasive surgical techniques and improved peri-operative care. It is expected 
that these and other factors will continue to influence both the frequency and the outcomes of 
cardiac surgery in the future.3
Cardiac surgery has always been a field of medicine in which a fair share of blood products is 
used. This is because cardiac surgery can go with substantial blood loss. Moreover, the use of 
heart-lung machines causes hemodilution and the patients undergoing cardiac surgery need a 
relatively high hemoglobin concentration due to impaired oxygen delivery.4 The consumption 
of blood products in cardiac surgery decreased over the last decades.5 When the heart- lung 
machine first enabled cardiac surgery, the duration of surgery could extent up to ten hours and 
the heart-lung machines were much bigger than the modern ones (requiring a larger volume 
often primed with blood products). Nowadays, most cardiac surgeries take about four to six hours 
and heart-lung machines are much smaller and more efficient, often primed with a mix of colloids 
and crystalloids. This makes that less blood products are required than in the past.6 Still cardiac 
surgery remains a major consumer of blood products, approximately 10-15% of the overall supply 
of donor blood is consumed by cardiac surgery patients.7,8
In many cases it remains unclear when and if a patient benefits from the transfusion of blood 
products and there is still much uncertainty about the possible benefits and harms of blood 
transfusion in patients undergoing cardio- thoracic surgery.
Risk models in cardiac surgery, the EuroSCORE II
One of the most used risk models in cardiac surgery is the EuroSCORE. The first EuroSCORE 
became available in 1999 and provided a simple additive and logistic model.9 The EuroSCORE 
was designed to predict in-hospital mortality in cardiac surgery patients, and for years it did so 
with great accuracy. However, over the years it became clear that the calibration of this model 
became less accurate; the mortality risk was increasingly overestimated.10–12 This overestimation 
was caused by substantial improvements in cardiac surgery, which in turn substantially decreased 
mortality rates.13 Therefore, the EuroSCORE was modified and renamed EuroSCORE II in 2011. In 
this new risk model adjustments in the choice of prognostic variables were made and the model 
was re-calibrated. When a new risk model is launched it is important to externally validate the 
model in the local population before it is implemented in clinical practice to prevent over- or 
underestimation of peri-operative risks.14,15 After the presentation of the EuroSCORE II a number 
of validation studies have been performed. The EuroSCORE II was compared with its predecessor 
the EuroSCORE I and with other cardiac surgery risk models, like the Society of Thoracic Surgeons 
score (STS-score).16–18 Results of these validation studies were conflicting, although the EuroSCORE 
II was often the best performing model.16,17
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To examine if the EuroSCORE II is a better fitting risk model for cardiac surgery patients in the 
Netherlands than its predecessor, the EuroSCORE I, we performed a prospective validation study 
comparing both risk models. This validation study is presented in chapter two of this thesis.
Transfusion triggers
Over the last decade transfusion practices regarding red blood cells have been subjected to 
major changes, especially in patients undergoing cardiac surgery.19–21 Both anemia as well as red 
blood cell transfusions can cause serious adverse events and the risks of both are put well forward 
in literature.22–25 Over the last few years, as the awareness of the risks of red blood cell transfusions 
increased, research concentrated on finding the lowest hemoglobin level that was tolerated 
in patients. In these studies, in search of a more restrictive transfusion strategy a transfusion 
threshold of seven g/dL was studied extensively.26,27
The results of these studies resulted in a decrease in the use of red blood cell transfusions, without 
an apparent effect on 30-day mortality.28 But although these studies showed no inferiority of a 
restricted transfusion threshold in cardiac surgery patients, other studies found more adverse 
outcome using a restrictive transfusion trigger and expressed their concern whether a hemoglobin 
level as low as seven g/dL is safe for patients with a predisposition of cardiac ischemia.29,30
Current transfusion guidelines, like the guidelines of the American Association of Anesthesiologists 
(ASA) or the Dutch transfusion guidelines, use relatively fixed transfusion thresholds.4,31 These 
guidelines provide in a higher transfusion threshold in more severely ill patients (based on 
their ASA classification).4 But although age and severity of disease is taken into account in 
transfusion guidelines, the relative amount of hemoglobin decrease during surgery is ignored. 
In 2008 a study analyzed the effect of relative hemoglobin decrease during cardiac surgery.30 
A more than 50 percent hemoglobin decrease was associated with a higher occurrence of the 
composite endpoint consisting of in-hospital mortality, stroke and/or kidney failure. This suggests 
that the magnitude of hemoglobin decrease may also play a role in postoperative morbidity 
and/or mortality. Until now, no other studies confirmed or refuted these remarkable findings. 
Chapter three of this thesis shows a study examining the influence of a relative ( > 50% decrease) 
hemoglobin decrease on adverse postoperative outcome.
Jehovah’s Witnesses, anemia and red blood cell transfusion
As mentioned above both anemia and red blood cell transfusion can cause morbidity and 
mortality.22–25 In cardiac surgery, there is no consensus regarding the intra-operative hemoglobin 
level at which the beneficial effects of red blood cell transfusions outweigh the risks.5,30 To study 
the effect of uncorrected anemia ( i.e. without the confounding interference of red blood cell 
transfusions) one can study a population like Jehovah’s witnesses, who refuse blood transfusions 
on account of their religious beliefs. A disadvantage of studying Jehovah’s witnesses is the 
possible introduction of selection bias. Caution is warranted when designing a study which 
includes Jehovah’s witnesses to avoid this pitfall.
Previous studies show that selected Jehovah’s witnesses can undergo bloodless cardiac surgery 
with the same results as non-Jehovah’s witnesses, although it is not known whether this is true 
for Jehovah’s witnesses who develop intra-operative anemia.32–37 Blood sparing measures like 
Chapter 1
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isovolemic hemodilution, administration of tranexamic acid and (if the patient consents) cell saver 
systems can be used during surgery to decrease blood loss as much as possible.33 In addition to 
that, many Jehovah’s witnesses are subjected to a pre-operative preparation regime in which 
erythropoietin, iron supplements and/or folic acid are administered when deemed necessary to 
achieve an optimal Hb.38,39 All these measures in combination with extended coagulation during 
surgery make it possible to perform major surgery without using any blood products.40
Some studies have compared Jehovah’s witnesses with patients who did receive red blood cell 
transfusion during surgery.34,36,41 Although these studies show no differences in the postoperative 
outcome between Jehovah’s witnesses and non-Witnesses, one cannot deduce from these 
studies that the patients who were transfused received their red blood cell redundantly, because 
they could have been worse off if they did not receive the transfusion. In the fourth chapter 
of this thesis we examine the effect of uncorrected anemia in Jehovah’s witnesses and the role 
of a single red blood cell transfusion using Jehovah’s witnesses as well as transfused and non-
transfused non-Witnesses who suffer from an intra-operative anemia.
Red blood cell allo-immunisation
One of the unwanted effects of red blood cell transfusion is the formation of allo-antibodies 
against incompatible donor antigens. These allo-antibodies could lead to delayed and acute 
hemolytic transfusion reactions which could be fatal. Also, logistic inconvenience trying to 
find a matching red blood cell unit for a patient with allo-antibodies can be challenging and 
time consuming. In cardiac surgery 2-10% of the patients form allo-antibodies to red blood cell 
transfusion after a single transfusion event.42–45
Red blood cell transfusions which are ABO-D compatible, but are incompatible for additional 
blood group systems do not always lead to the formation of allo-antibodies. So, unraveling 
possible causes of the formation of these antibodies is important to develop preventive strategies. 
Genetic, environmental and pro-inflammatory factors have been studied as possible causes of 
the formation of allo-antibodies.46–48 It has been hypothesized that the storage time of red blood 
cells also influences this process.49,50
The effect of red blood cell storage time is unclear and has been widely debated. During storage 
red blood cells undergo a series of morphological and biochemical changes known as the storage 
lesion.51 Some studies reported adverse outcomes after transfusion of ‘older’ red blood cell units 
on account of this storage lesion while others did not.52–55 One study, performed in a mouse 
model, showed an association between storage time and the formation of allo-antibodies.56 Two 
(observational) studies have assessed the effect of red blood cell storage time on the formation 
of allo-antibodies.49,50 Both studies suggested that storage time did not affect allo- immunization, 
but this may have been due to limitations in the design. Both studies lacked information on the
exact red blood cell unit carrying the cognate incompatible antigen (i.e. the red blood cell unit 
which caused the formation of allo-antibodies). In the fifth chapter of this thesis we present a 
study analyzing the influence of red blood cell storage time on the formation of allo-antibodies 
in which we did identify the red blood cell unit deemed responsible for the allo-immunization. To 
achieve this we focused our study on the Kell-antigen. Because this antigen has a relatively low 
frequency in Caucasian populations, the probability that a patient receives multiple incompatible 
General introduction
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K-positive units, each with a different storage interval, during a transfusion event is low.57 Therefore
it was possible to determine the exact storage time of the red blood cell unit which caused 
immunization. Also the storage times of the concomitantly transfused K-negative units were 
analyzed because one could hypothesize that those units could play an enhancing or dampening 
role in the formation of allo-antibodies.
Safety of platelet transfusions in cardiac surgery
When prescribing red blood cells the benefits and adverse effects of transfusion should be 
weighted carefully.
The same applies to platelet concentrates. In cardiac surgery excessive bleeding is not 
uncommon due to both surgical and hemostatic causes.58–60 Among the hemostatic causes 
of bleeding, platelet dysfunction plays an important role. The use of cardiopulmonary bypass 
and/or pre-operative anti-platelet drug therapy are well known causes for an impaired platelet 
function during and after cardiac surgery.27,61 To treat or prevent bleeding which is presumed to 
be the result of platelet dysfunction, platelet transfusions are often prescribed in cardiac surgery 
patients.59 Also, because an increasing number of patients is having cardiac surgery while they 
are still on anti- platelet medication or anti-coagulants, prophylactic platelet transfusions are 
more and more prescribed.62–64 Despite the current guidelines, transfusion policies regarding 
platelet concentrates remain divergent which is shown by the wide variety of platelet use among 
different hospitals.65,66
The efficacy of platelets remains unclear and studies that analyzed the safety of platelet 
concentrates show conflicting results.67–71 Some studies found associations between platelet 
transfusion and vasoplegia, renal failure, infections and trombo-embolic complications like 
myocardial infarction or stroke.68,70,71 Others examining the same associations found none.67,69 In 
the sixth chapter of this thesis we examine the safety as well as the efficacy of a single platelet 
concentrate by comparing patients who received one platelet concentrate intra-operatively with 
matched patients who received no blood products at all.
In this thesis we address the question when the transfusion of blood products is in the best 
interest of the patient undergoing cardiac surgery. We specifically study risk models, does the 
EuroSCORE II perform better than its predecessor? Transfusion triggers, is an addition to the 
absolute transfusion trigger that is used now feasible for certain patient categories undergoing 
cardiac surgery? We also look at bloodless surgery and the effects of a single red cell transfusion 
as well as platelet transfusions and the postoperative effects of a single platelet transfusion and 
antibody formation and the possible role of storage time.
Chapter 1
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The EuroSCORE I was one of the most frequently used pre-operative risk models in cardiac 
surgery. In 2011 it was replaced by its successor the EuroSCORE II. This study aims to validate the 
EuroSCORE II and to compare its performance with the EuroSCORE I in a Dutch hospital.
Methods
The EuroSCORE II was prospectively validated in 2296 consecutive cardiac surgery patients 
between April 1th 2012 and January 1th EuroSCORE I and EuroSCORE II and the Area Under the 
Curve was calculated to assess discriminative power. Calibration was assessed by comparing 
observed versus expected mortality. Additionally, analyses were performed in which we stratified 
for type of surgery and for elective versus emergency surgery.
Results
The observed mortality was 2.4% (55 patients). The discriminative power of the EuroSCORE II 
surpassed that of the EuroSCORE I (area under the curve EuroSCORE II 0.871 95%, Confidence 
interval 0.832-0.911, area under the curve additive EuroSCORE 0.840, CI 0.798-0.882, area under 
the curve logistic EuroSCORE I 0.761, CI 0.695-0.828). Both the additive and the logistic EuroSCORE 
I overestimated mortality (predictive mortality additive EuroSCORE I median 5.0%, inter quartile 
range 3.0-8.0%, logistic EuroSCORE I 10.7%, inter quartile range 5.8-13.9), while the EuroSCORE II 
underestimated mortality (median 1.6%, inter quartile range 1.0-3.5). In most stratified analyses 
the EuroSCORE II performed better.
Conclusion
Our results show that the EuroSCORE II produces a valid risk prediction and outperforms the 
EuroSCORE I in elective cardiac surgery patients.
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Introduction
In a growing population of patients undergoing cardiac surgery (including older and more 
vulnerable patients), an accurate pre-operative risk assessment has become indispensable.1 An 
often-used method for risk assessment in cardiac surgery is the European System for Cardiac 
Operative Risk Evaluation better known as the EuroSCORE (ES). The first ES became available 
in 1999 and provided a simple additive and logistic risk calculation model based on European 
adult cardiac surgery patients, and was widely implemented.2 The ESI was validated in the 
Netherlands for both short as long term mortality and morbidity.3 Over time, it became clear that 
the EuroSCORE I (ESI) overestimated the 30-day and 90-day mortality risk.4,5 This overestimation 
was caused by improvements in peri-operative patient care resulting in substantially reduced 
mortality rates and evoked the need for a renewed risk model.1
In 2011 the successor, the EuroSCORE II (ESII), was presented. As with all new risk models it is 
important to externally validate this model in patients other than the sampled patient population 
from which the risk model was developed.6 Differences in patient populations influence risk 
models’ performance and determines whether or not the model is fit for use in a particular 
population.7
Validation studies that have been published so far show ambiguous results when comparing the 
ESII with other risk models like the ESI and the Society of Thoracic Surgery score.8,9 Furthermore, 
several studies used data which were collected before the ESII was developed and several studies 
validated the study for surgical procedures for which the ESII was not intended.10–12
In 2003 we performed the first study validating the ESI in cardiac surgery patients in the 
Netherlands.3 In succession of that, the present study aims to validate the ESII risk model in 
patients undergoing cardiac surgery in the Netherlands and also compare ESII performance with 
the performance of the additive and logistic ESI.
Materials and Methods
Data collection
The analyses were performed with data from the Amphia Cardiac Surgery Blood Management 
Study. Details of this study have been described earlier.13 In this ongoing cohort study, peri-
operative data are prospectively collected of all consecutive cardiac surgery patients since 1997. 
Data are collected in a distributed proprietary database during the complete peri-operative 
course. Variables regarding pre-operative co-morbidities, drug therapy, routine pre-, intra- and 
postoperative lab analysis, complications and postoperative outcome are collected in the 
Amphia hospital, Breda, the Netherlands. The Amphia hospital is a non-university hospital with 
the possibility of transferring special patient categories to tertiary hospitals.
All variables necessary to calculate both the ESI and the ESII are present in the database. After 
publication of the ESII the data-dictionary was updated to reflect ESII additions and changes. 
The ESII update was implemented from April 2012 on. The database is compliant with the Dutch 
National Cardiac Surgery Registry and the Dutch National Intensive Care Registry.14
Data collection took place between April 1st 2012 and January 1th 2014.
Prospective validation of the EuroSCORE II risk model in a single Dutch cardiac surgery center. 
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Patient sample and analyses
All consecutive patients who underwent cardiac surgery were included regardless their type of 
surgery. For each patient the additive and logistic ESI as well as the ESII were calculated using 
the formula’s available at the EuroSCORE website (www.euroscore.org). The discriminative 
power of each risk model was assessed by plotting the Receiver Operator Curves (ROC curves) 
of the different ES on in-hospital mortality, and comparing the Area Under the Curve (AUC). 
The calibration of the different risk models was examined comparing the observed versus the 
expected values for in-hospital mortality rates. This way we could assess whether the ES (low or 
high) corresponded with the observed mortality. We performed the same analyses in subgroups 
according to type of surgery in 4 categories: Coronary Artery Bypass Graft (CABG), CABG combined 
with other surgery, valve surgery, miscellaneous procedures and according to the urgency of the 
procedure: emergency versus elective surgery. Emergency surgery was defined as surgery which 
had to be performed as soon as possible but at least within 24 hours after admittance.
Results
Patient characteristics
Our cohort consisted of 2296 patients; pre- and intra-operative patient characteristics are shown 
in table 1. A total of 662 patients (28.8%) were female, the median age was 70 years (interquartile 
range [IQR] 63-76). The overall mortality in our cohort was 2.4% (55 patients).
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- II  694 (30.2)
- III  484 (21.1)- IV  176 (7.7)LMCA > 50% occluded 4 299 (13.0)
Left ventricle hypertrophy 24 536 (23.3)
Pulmonary artery pressure > 40 mmHg - 58 (2.5)
Atrial fibrillation 1 399 (17.4)
Extra cardiac arteriopathy - 311 (13.5)
Hypertension
Pre-operative Hb level (g/dL) 















- moderate  377 (16.4)
- poor  136 (5.9)
- very poor  25(1.1)Smoking 19 366 (15.9)
Insulin dependent diabetes - 284 (12.4)
Endocarditis - 28 (1.2)
Chronic renal failure** - 50 (2.2)
COPD - 267 (11.6)
Poor mobility - 167 (7.3)
Pre-operative use of inotropic agents - 25 (1.1)
Respiratory insufficiency - 65 (2.8)
Jehovah’s witnesses 2 32 (1.4)
Emergency surgery - 261 (11.4)
Aortic valve pathology - 793 (34.5)
Mitral valve pathology







- CABG + other surgery  319 (13.9)- Valve  615 (26.8)
- Miscellaneous surgery  303 (13.2)
Off-pump procedure
Additive EuroSCORE I 










Intra-operative variables:   
Time in surgery (min)
CPB time (min) 
Clamp time (min) 










* Variables are presented as number (%) or median (IQR)
**Creatinine level above 177 mmol/L
  
Performance of the EuroSCORE II
We observed that although the discriminative power of both the additive as well as the logistic 
ESI was good, it was surpassed by the ES II (AUC additive ESI 0.840, 95% Confidence Interval 
(CI) 0.798-0.882, logistic ESI 0.761, CI 0.695-0.828, AUC ESII 0.871, CI 0.832-0.911). ROC curves are 
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displayed in Figure I. The ESII underestimated observed mortality while the additive and the 
logistic mortality overestimated mortality (ESII observed versus expected (O/E) ratio 1.50 vs ESI 
additive 0.48 vs ES logistic 0.22, results are displayed in table 2).




Figure 1: ROC-curves for the additive and logistic ESI and the ESII
 
Table 2: Discrimination and calibration parameters in total cohort (n=2296)
 











Additive EuroSCORE I 0.840 (0.798-0.882) 55 (2.4) 5.0 (3.0-8.0) 0.48 
Logistic EuroSCORE I 0.761 (0.695-0.828) 55 (2.4) 10.7 (5.8-13.9) 0.22 
EuroSCORE II 0.871 (0.832-0.911) 55 (2.4) 1.6 (1.0-3.5) 1.50
 
*  IQR - Inter Quartile Range
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EuroSCORE II  performance in different types of surgery
A total of 1059 patients underwent a CABG, 319 patients underwent a CABG in combination with 
another procedure, 615 patients underwent surgery regarding one or more heart valves and 303 
patients underwent miscellaneous kinds of cardiac surgery. Table 3 shows the observed versus 
























Additive EuroSCORE I 0.900 (0.838-0.962) 13 (1.2) 4.0 (3.0-6.0) 0.30 
Logistic EuroSCORE I 0.691 (0.536-0.846) 13 (1.2) 10.6 (4.8-13.7) 0.11 
EuroSCORE II 0.884 (0.809-0.958) 13 (1.2) 1.4 (0.93-2.6) 0.86 
CABG + other procedure (n=319)
Additive EuroSCORE I 0.739 (0.648-0.831) 14 (4.4) 7.0 (5.0-9.0) 0.63 
Logistic EuroSCORE I 0.812 (0.695-0.929) 14 (4.4) 10.3 (5.5-13.8) 0.43 
EuroSCORE II 0.693 (0.566-0.820) 14 (4.4) 3.4 (2.0-6.5) 1.29 
 
Valve (n=615)
Additive EuroSCORE I 0.833 (0.722-0.943) 13 (2.1) 7.0 (5.0-9.0) 0.30 
Logistic EuroSCORE I 0.755 (0.594-0.917) 13 (2.1) 11.2 (8.8-14.2) 0.19 
EuroSCORE II 0.866 (0.768-0.964) 13 (2.1) 1.5 (1.0-3.1) 1.40 
Miscellaneous procedures (n=303)
Additive EuroSCORE I 0.819 (0.732-0.907) 15 (5.0) 5.0 (2.0-9.0) 1.00 
Logistic EuroSCORE I 0.784 (0.692-0.876) 15 (5.0) 10.3 (4.5-14.2) 0.49 
EuroSCORE II 0.912 (0.862-0.962) 15 (5.0) 1.5 (0.7-4.7) 3.33
 
Discrimination and calibration according to urgency
 
Elective surgery (n=2035)













Logistic EuroSCORE I 0.720 (0.621-0.818) 30 (1.5) 10.5 (5.2-13.7) 0.14
EuroSCORE II 0.839 (0.784-0.894) 30 (1.5) 1.5 (0.92-2.9) 1.00
Emergency surgery (n=261)     
Additive EuroSCORE I 0.726 (0.616-0.836) 25 (9.6) 10.0 (7.0-13.0) 0.96
Logistic EuroSCORE I 0.729 (0.631-0.826) 25 (9.6) 12.9 (9.2-17.5) 0.74
EuroSCORE II 0.816 (0.736-0.896) 25 (9.6) 5.9 (2.2-13.2) 1.63
 
*  IQR - Inter Quartile Range
** Observed versus Expected ratio
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Figure 2 Receiver Operator Characteristic curves for the additive and logistic EuroSCORE I and the EuroSCORE II. A. Patients undergoing a 
CABG (n=1059). B. Patients undergoing valve surgery(n=615). C. Patients undergoing a CABG in combination with any other procedure (n=319). 
D. Patients undergoing miscellaneous cardiac surgical procedures (n=303). 
 
  
Figure 2. Receiver Operator Characteristic curves for the additive and logistic EuroSCORE I and the EuroSCORE II. 
A. Patients undergoing a CABG (n=1059). B. Patients undergoing valve surgery(n=615). C. Patients undergoing a 
CABG in combination with any other procedure (n=319). D. Patients undergoing miscellaneous cardiac surgical 
procedures (n=303).
In patients who underwent a CABG in-hospital mortality was 1.2%. The additive ESI had the best 
discriminative power (AUC 0.900, CI 0.838-0.962) and the ESII was the best calibrated risk model 
(O/E ratio ESII 0.86). In patients who underwent a CABG in combination with other surgery in-
hospital mortality was 4.4%. Discriminative power of the logistic ESI was highest (AUC 0.812, 
CI 0.695-0.929). Although mortality was underestimated by the ES II, the ESI overestimated the 
mortality even more therefore the ESII provided a better calibration (O/E ratio ESII 1.29).
In the patients who underwent isolated valve surgery the mortality was 2.1%. The ESII had the 
highest discriminative power and was best calibrated (AUC 0.866, CI 0.768-0.964, O/E ratio 1.40). 
Chapter 2
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Figure 3: Receiver Operator Characteristic curves for the additive and logistic EuroSCORE I and the EuroSCORE II. A. Patients 
undergoing elective surgery (2035). B. Patients undergoing emergency surgery (261). 
 
In patients who underwent miscellaneous cardiac surgery, mortality was 5.0%. The ESII showed 
best discrimination (AUC 0.912, CI 0.862-.962).Best calibration was performed by the additive ESI 
(O/E ratio 1.00)
EuroSCORE II performance in emergency surgery
A total of 261 patients underwent emergency surgery and 2035 patients underwent elective 
surgery. Table 3 shows the observed versus expected mortality in patients who underwent 
elective or emergency surgery (ROC curves are displayed in figure 3). In patients who underwent 
elective surgery the ESII had the highest discriminative power and was best calibrated (AUC 0.839, 
CI 0.784-0.894, O/E ratio1.00). In patients who underwent emergency surgery the ESII had the 
highest discriminative power but the additive ESI was better calibrated (ESII AUC 0.816, CI 0.736-
0.896, O/E ratio 1.63 and ESI AUC 0.726, CI 0.616-0.836, O/E ratio 0.96).
Figure 3. Receiver Operator Characteristic curves for the additive and logistic EuroSCORE I and the EuroSCORE II. A. 
Patients undergoing elective surgery (2035). B. Patients undergoing emergency surgery (261).
Discussion
Main Findings
In this validation study, we found that the ESII is a well-calibrated risk model with a good predictive 
value. The ESII underestimated the mortality in some subgroups while the ESI overestimated the 
observed mortality. Nevertheless the expected mortality of the ESII approached the observed 
mortality more closely than the ESI and therefore the ESII outperformed the ESI in most patients. 
Whether this is also true for patients who underwent CABG surgery in combination with another 
procedure, miscellaneous surgery or emergency surgery in this study is not certain due to small 
sample size of the subgroups.
Prospective validation of the EuroSCORE II risk model in a single Dutch cardiac surgery center. 
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Limitations and Strengths
A limitation of our study is that it is a single centre study, which could impair the generalizability of 
our results. There is little reason to believe that the patient population in the Amphia hospital will 
differ a lot from other peripheral hospitals in the Netherlands. Nevertheless bias due to population 
differences could not be ruled out. Furthermore, sample sizes of some subcategories used in our 
subgroup analyses (CABG in combination with another procedure, miscellaneous surgery and 
emergency surgery) might be too small to exclude random error. Also, validating the ESII for 30-
day and 90-day mortality was not possible with our present data.
Strengths of this validation study are that our data were collected prospectively after the 
implementation of the ESII in clinical practice. The database used is accurate and contained very 
few missing data.
In order to validate a risk model like the ESII,  validation studies must satisfy certain requirements. 
In this study we avoided pitfalls which could lead to biased results. For example, the ESII was 
developed based on data collected in a 12 week period in 2010 and was intended for prospective 
use.1 Some studies have validated the ESII based on data acquired before 2010, and some studies 
included patients over an extended period of time.
This could lead to biased results because of changes and improvements made in daily practice.15 
An example of this bias is illustrated in a study, which validates the ESII in two different time 
periods. First, the ESII was validated in patients who had surgery between 2003 and 2012. The 
results from the analyses showed that although the ESII had the highest discriminative power, 
the STS score had a better calibration. After this analysis, the ESII was validated in a subgroup 
of patients who had surgery between 2008 and 2012. Results from these analyses show that 
the ESII (based on patient data collected in 2010) was the best overall risk model.16 Also, there 
are studies in which the ESII has been validated in surgical procedures for which the ESII was 
never intended (for example in trans-catheter aortic valve implantation). This also could lead to 
suboptimal performance.17 And third, some validation studies present incomplete data or use 
inaccurate statistical methods.
For example basing their conclusions solely on a non-significant Hosmer-Lemeshow test, instead 
of showing the complete data.17 In this present study we avoided these known pitfalls.
Comparison with other EuroSCORE II validation studies
The observed in-hospital mortality in our study (2.4%) differed slightly with the overall mortality 
of cardiac surgery procedures in the Netherlands (3.0%) or in neighboring countries like the UK 
(2.7%).18,19 Baseline characteristics of our cohort and the patient sample on which the original 
ESII was based were nearly identical. The only variable that differed between our study and the 
original sample was insulin-dependent diabetes (12.4% in our cohort versus 7.6%). The mortality 
rates of the original patient sample (3.9%) and the mortality rates in our cohort differed 1.5%.
Ever since the publication of the ESII in 2012, more than 50 studies concerning the ESII have been 
published with varying results. Our results agree with a majority of these studies.20–24 Two studies 
also analyzed the performance of the ESII according to type of surgery using the same categories 
we used. Curiously, although the ESII performed well, these studies found that the ES I was the 
overall best performing risk model in elective surgery.25,26 This is due to a higher mortality rate 
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than in our cohort. Why the mortality of these two cohorts differ with ours is not precisely known, 
but these differences could be due to different population characteristics like NYHA class and 
gender.
In a previous study, focusing solely on the performance of the ESII in patients who had emergency 
surgery, the ESII outperformed the ESI, although both the ES showed a poor calibration and 
discrimination.27 In our cohort the overall performance of the models was worse in patients who 
underwent emergency surgery than in patients who did not. In our cohort of emergency patients 
the ESII had a good discriminative power but a rather poor calibration, while the additive ES I 
had a good calibration. It is possible that other logistic factors, like for example, time to diagnosis 
or time it takes to get a patient to a specialized centre play a more important role in the risk 
evaluation of emergency patients than factors included the ES.
One study retrospectively evaluated the performance of the ESII in the Netherlands with similar 
results as we found.24 However this was a small study examining only one hundred patients who 
underwent CABG surgery combined with mitral- or aortic valve surgery.
Implications for practice and future research
Before implementing a risk model in daily practice it is important to externally validate the model 
in local populations.6 Our findings show that the ESII is a good risk predictor which outperforms 
its predecessor. Based on the results in our cohort we recommend using the ESII as standard tool 
for risk prediction in patients undergoing cardiac surgery.  A significant part of our cohort existed 
of patients undergoing an isolated CABG with relatively short CPB times. Therefore we also 
recommend that all hospitals using or planning to use ESII should validate the ESII in their setting 
because for example differences in CPB time or operation type could influence the predictive 
value of the ESII.
Another topic of future research should be identifying other variables that could increase the 
accuracy of the ESII, especially with regards to emergency surgery and/or high risk patients 
because it seems the ESII has the least predictive value in those populations.
In conclusion, the ESII is a good predictive model of short term mortality in cardiac surgery and it 
is better calibrated than its predecessor the ESI in patients undergoing elective surgery.
Prospective validation of the EuroSCORE II risk model in a single Dutch cardiac surgery center. 
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It has been suggested that a decrease of at least 50% from the preoperative hemoglobin (Hb) 
level during cardiac surgery is associated with adverse outcomes even if the absolute Hb level 
remains above the commonly used transfusion threshold of 7.0 g/dL. In this study the relation 
between intraoperative Hb decline of at least 50% and a composite endpoint was analyzed.
Study Design and Methods
This single-centre study comprised 11,508 patients who underwent cardiac surgery and had 
normal preoperative Hb levels (12.0-16.0 g/dL in women, 13.0-18.0 g/dL in men) between January 
2001 and December 2011. Logistic regression modeling was used. The composite endpoint 
comprised in-hospital mortality, stroke, myocardial infarction and renal failure.
Results
Patients whose Hb did not decrease at least 50% and remained above 7 g/dL were used as 
reference (n=9672). A total of 363 (3.2%) patients had an intraoperative Hb of less than 7 g/dL 
during surgery but a Hb decrease less than 50%; 876 patients (7.4%) showed both a nadir Hb 
less than 7g/dL and a Hb decrease of at least 50%, while 597 (5.2%) had a Hb decrease of at least 
50% and a nadir Hb of at least 7 g/dL. In this last group the incidence of the composite endpoint 
was higher than in patients in the reference group (adjusted odds ratio,1.27; 95 % confidence 
interval,1.14-1.41).
Conclusions
Our findings show that a decrease at least 50% from baseline Hb during cardiac surgery is 
associated with adverse outcomes, even if the absolute Hb level remains above the commonly 
used transfusion threshold 7.0 g/dL.
Chapter 3
530970-L-bw-Hogervorst
Processed on: 3-5-2019 PDF page: 35
35  
Introduction
Cardiac surgery is associated with intraoperative blood loss and hemoglobin (Hb) decrease, 
which can lead to an anemic state. Anemia is a recognized risk factor for operative mortality; 
additionally serious and invalidating postoperative morbidity like stroke, myocardial infarction, 
and renal failure have been described.1–4 Transfusions with red cells (RBCs) serve to prevent the 
occurrence of anemia-related complications, but have also been associated with severe side 
effects.5,6 Therefore, it is sometimes unclear whether an anemic patient will benefit from a RBC 
transfusion or not. 
Measuring tissue oxygen delivery would be the best way to measure a critically low Hb level 
that may benefit from a RBC transfusion, but since this is not yet possible surrogate indications 
for transfusion are used. In cardiac surgery often a transfusion threshold of 7.0 g/dL is used. It 
has been suggested that the extent of an acute decrease in Hb might pose a greater risk for 
postoperative complications than a Hb decreasing below 7.0 g/dL.7
This could imply that a relative transfusion threshold might be more useful in preventing ischemia-
related complications than an absolute transfusion trigger. This would especially be the case in 
patients with a ‘higher’ preoperative Hb level, because they must tolerate a larger Hb decrease 
before being transfused with RBCs when a fixed transfusion trigger is used. In the literature, the 
use of a relative transfusion trigger of 50% Hb decrease has led to fewer postoperative adverse 
events.7
Our primary objective was to examine the association between intraoperative acute anemia 
- defined as a Hb decrease of 50% or more – on a composite endpoint of postoperative 
complications. Our secondary objective was to analyze the relation between RBC transfusions 
and the composite endpoint in patients with an intraoperative Hb decrease of 50% or more with 
a nadir Hb of higher than 7 g/dL.
Materials and Methods
This study complied with the Declaration of Helsinki (2012-2013 revision. The local research ethics 
committee approved this study and the need for informed consent was waived.
Study population
We performed a single-centre cohort study that included 11,580 consecutive patients who 
underwent cardiac surgery in the Amphia Hospital in Breda, the Netherlands.
Annually, approximately 1500 patients undergo cardiac surgery at the Amphia Hospital. After 
surgery, patients were admitted at a 26-bed, level III intensive care unit.
Patients undergoing all types of on-pump cardiac surgery from January 1, 2001 until December 31, 
2011 were included. To avoid bias of preexistent anemia and polycytemia, we excluded patients 
with an abnormal Hb level. Therefore, we only included patients with a preoperative Hb between 
12.0 and 16.0 g/dL in women and 13.0 and 18.0 g/dL in men according to the definition of the 
World Health Organization (WHO).8 All RBC transfusions prescribed to patients were allogeneic 
and leukoreduced. Patients of whom no perioperative Hb levels were available were excluded.
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Decisions regarding patient care or perioperative transfusions were left to the attending 
anesthesiologist and/or surgeon, according to the transfusion guidelines of the American 
Association of Anesthesiologists and the Dutch transfusion guideline.9,10
On the intensive care unit and the ward, transfusions were prescribed by the attending physician 
based on the assumed cardio and respiratory status of the patient. This Dutch guideline stated 
that RBC transfusion is usually indicated when the Hb level is < 7 g/dL and rarely higher than 9 
g/dL. In case of Hb levels between 7 and 9 g/dL cardiopulmonary reserve, age, comorbidity and 
blood loss determines the transfusion threshold. In practice a transfusion trigger of 7 g/dL was 
applied.
Data collection
Data collection for this cohort started January 1, 1997. Intraoperative Hb data were not collected 
until 2001. To answer our specific research question, patients who underwent cardiac surgery prior 
to January 1, 2001, were therefore excluded. Thus, our cohort comprised patients who underwent 
on-pump cardiac surgery from January 1, 2001, until December 31, 2011. Data collection was 
compliant with the National Cardiac Surgery Registry and the National Intensive Care Registry.11 
All data were acquired from pre-, intra-, and postoperative routine blood draws and medical files.
Measurements
The preoperative Hb level was routinely measured in all patients and the last preoperatively 
measured Hb level was used as preoperative Hb in our study. Intraoperative Hb was measured at 
the induction of anesthesia, 30 minutes after the start of cardiopulmonary bypass (CPB), and after 
heparin reversal before chest closure. Additional Hb measurements were left to the discretion of 
the attending anesthesiologist and/or surgeon and were mostly performed when the patient’s 
condition required strict monitoring. The lowest intraoperative Hb was taken as the nadir Hb. 
Only patients whose pre- as well as intraoperative Hb level were available were included in the 
present analysis.
The Hb decrease in percentage was calculated as: [(preoperative Hb – nadir Hb)/preoperative 
Hb] x 100.
Outcome definitions
Our primary aim was to analyze the effect of a Hb decrease of 50% or more during cardiac surgery 
on a composite endpoint of possible anemia-related complications comprising in-hospital death 
and/or stroke and/or acute kidney failure and/or myocardial infarction. Stroke was defined as a 
new persistent cerebrovascular event leading to neurological defaults and was diagnosed by a 
neurologist. Acute kidney failure was defined as the
need for postoperative renal replacement therapy when this was not indicated before and/or an 
increase in serum creatinine of more than 100%. The diagnosis postoperative myocardial infarction 
was made based on either the occurrence of new Q waves on the electrocardiogram or ischemic 
ST changes in combination with abnormal postoperative troponin T levels (troponin T level > 
0.5 µ/L for coronary artery bypass grafting (CABG) surgery, troponin T level > 0.8 µ/L for valve 
surgery and troponin T level > 1.0 µ/L for combined CABG and valve procedures). Both serum 
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creatinine and troponin T were routinely measured in every patient postoperatively. A secondary 
aim was to analyze the association between RBC transfusion and the composite endpoint in the 
four different categories independently, in particular because we were interested in the effect of 
RBC transfusion in patients with a Hb decrease of 50% or more.
Statistical analyses
We divided our cohort in four categories based on absolute and relative Hb decrease using the 
cut off points described previously. Specifically, we analyzed the association between a 50% Hb 
decrease or more and the composite endpoint in the presence and in the absence of a Hb level 
of less than 7 g/dL as this is a commonly used transfusion trigger.
The first (reference) category consisted of patients who had an intraoperative Hb decrease less 
than 50% and whose intraoperative nadir Hb remained higher than 7 g/dL. Furthermore, the 
categories consisted of patients who only had a Hb level of less than 7 g/dL (second category), 
only an intraoperative Hb decrease of 50% or more (third category), and both an intra-operative 
Hb level of less than 7 g/dL and a Hb decrease of 50% or more (fourth category).
Multivariable logistic regression models were used and crude as well as adjusted results are 
presented. Covariates were included in the adjusted analysis if they were considered a risk factor 
for the composite endpoint and their incidence differed between the four categories. Because 
of the etiological nature of our research question we also included covariates related to the 
exposure and the outcome irrespectively if there were differences between the four categories.12 
We adjusted for the following pre- and intra-operative variables;
Preoperative variables
Preoperative variables included age (as a continuous variable), sex, current smoking, preoperative 
Hb (g/dL), vascular disease (defined as having previous vascular surgery and/or intermittent 
claudication), liver cirrhosis (diagnosed by a positive biopsy and documented portal hypertension 
or previous periods of upper gastrointestinal bleeding due to portal hypertension or previous 
episodes of liver failure, coma or encephalopathy), hematologic malignancy (as diagnosed by 
a hematologist), left ventricle hypertrophy (diagnosed on echocardiography), atrial fibrillation, 
endocarditis (according to the Duke criteria), hypertension (diagnosis retrieved from patient’s 
history and/or treatment with antihypertensive drug therapy), chronic obstructive pulmonary 
disease (COPD; diagnosis retrieved from patient’s history and treatment with bronchodilators 
and/or corticosteroids), diabetes (defined as receiving any antidiabetic drug therapy), myocardial 
infarction ( as diagnosed by the referring cardiologist), aspirin use, clopidogrel use, use of 
anticoagulant drugs (heparin, low-molecular-weight heparin, coumarines or a combination), 
creatinine clearance (as a continuous variable), fibrinogen (g/dl; as categorical variable; <2 / 
> 2 g/dl), New York Heart association (NYHA) class, respiratory failure (defined as the need for 
mechanical ventilation), previous cardiac surgery, emergency surgery, type of surgery (CABG, 
CABG plus valve surgery, CABG plus other, valve surgery or other), cardiopulmonary resuscitation 
(CPR) 24h before surgery.
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Intra-operative variables
Intraoperative variables included use of antifibrinolytics (aprotinin, tranexamic acid, other), 
lowest intraoperative temperature (as continuous variable), CPB duration and operation duration 
(both as continuous variables), fresh frozen plasma (FFP) and platelet (PLT) transfusion (as binary 
variables), circulatory arrest, number of coronary arteries affected and cell-saver blood returned 
to patient (as binary variable). Missing data in the database were
imputed using a multiple imputations model.13
RBC transfusions were not included in the overall model because the relationship between RBC 
transfusions and the composite endpoint in the four patient groups was analyzed separately.
Effect modification occurs when the magnitude of the effect of the primary exposure on an 
outcome differs depending on the level of a third variable. In this situation, computing an overall 
estimate of association has little meaning. One common way of dealing with effect modification 
is to examine the association separately for each
level of the third variable.14,15 To analyze if there was any effect modification present in our study 
sample we did separate analyses, stratifying sex and type of surgery, for all patients with a Hb 
decrease of at least 50%.
Results
Characteristics of the study population
Data of 16,352 patients were collected of which 11,508 patients were included in the analysis. 
Figure 1 presents a flow chart of patient exclusions and number of patients available for analysis. 
Perioperative Hb data were missing for 3341 patients, so they were excluded. A total of 181 
patients were excluded because of missing intraoperative Hb data. An additional 1322 were 
excluded because they underwent off-pump surgery. A total of 1473 (12.8%) patients had a Hb 
decrease of 50% or more.
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 Figure 1. In- and exclusion flowchart
Perioperative characteristics of the included patients according to Hb loss of 50% or more and/or 
nadir Hb below 7 g/dL are shown in Table 1. As expected comorbidities, demographics, and risk 
factors differed between patients with different amounts of blood loss. For example patients with 
an intraoperative Hb loss of 50% or more and a nadir Hb of higher than 7 g/dl were more often 
male, had less often emergency surgery performed, had a higher preoperative Hb and were less 
frequently transfused. Also, they received less inotropic drugs.
Blood loss and anemia-related complications
Overall, anemia-related complications occurred in 2322 (20.7%) patients, of who 254 (2.2%) 
died, 952 (8.3%) had a stroke, 569 (5.0%) developed postoperative renal failure requiring renal 
replacement therapy and/or an increase in serum creatinine of more than 100% and 1176 
(10.3%) suffered a postoperative myocardial infarction. Some patients suffered more than one 
complication.
Compared to patients who did not lose 50% or more of their Hb and who remained higher 
than 7 g/dl (reference group, Category 1), patients in Category 3 with a Hb loss of 50% or more 
whose intraoperative nadir Hb remained higher than 7 g/dL did suffer more anemia-related 
complications (adjusted OR [aOR], 1.26; 95% Confidence Interval [CI] 1.13-1.41; table 2). In patients 
who had a Hb decrease of 50% or more and an intraoperative nadir Hb of less than 7 g/dL there 
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was also a positive association with the composite endpoint (aOR 1.12; 95% CI 1.02-1.22).
Patients who had a Hb decrease of less than 50% but who did experience a nadir Hb of less than 
7 g/dL during surgery had roughly the same odds to suffer from the composite endpoints as the 
patients in the reference category (aOR, 0.93; 95% CI, 0.82-1.06).
Effect modification and stratification
To examine potential effect modification by sex and type of surgery, we performed stratified 
analyses for males and females as well as for type of surgery (CABG and CABG in combination with 
other surgical procedures vs. remaining non-CABG surgeries). Patients with an isolated Hb level 
of less than 7 g/dL despite less than 50% Hb decrease were more often female (85%), which is 
often a cause of a different profile of comorbidities and outcomes. When we stratified our analysis 
for sex, a more distinct association between a Hb decrease of at least 50% and the composite 
endpoint was found in women. This could be explained by the fact that for a woman to reach a 
Hb decrease of 50% or more, it means that a much lower nadir Hb must be reached compared 
to men, even though, this association was not statistical significant (aOR, 1.40; 95% CI, 1.09-1.81).
When we examined CABG or combined surgery with CABG combined  versus other surgical 
procedures,  no apparent modifications of the effect of Hb decrease on the composite endpoint 
were found.  These results are displayed in table 2A.
Chapter 3
530970-L-bw-Hogervorst































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Processed on: 3-5-2019 PDF page: 42
 42 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2A: Patients with more than 50% Hb decrease in relation to the composite endpoint








































Category 3 Male 511 + - 1.12 1.02-1.22 0.016 1.22 1.08-1.39 0.002 
Category 4 Male 374 + + 1.67 1.51-1.83 <0.001 1.13 0.98-1.31 0.092
Category 3 Female 86 + - 1.04 0.84-1.27 0.735 1.40 1.09-1.81 0.009
Category 4 Female 502 + + 1.44 1.32-1.57 <0.001 1.05 0.93-1.19 0.444
Category 3 CABG 491 + - 1.07 0.97-1.19 0.170 1.24 1.07-1.43 0.003
Category 4 CABG 711 + + 1.46 1.34-1.59 <0.001 1.10 0.97-1.24 0.153
Category 3 Non-CABG 106 + - 1.19 1.03-1.37 0.015 1.26 1.05-1.51 0.013
Category 4 Non-CABG 165 + + 1.95 1.77-2.14 <0.001 1.19 1.04-1.36 0.014
 
* Adjusted for: acetylic salicylic acid, clopidogrel and anti-coagulant drug use, preoperative fibrinogen <2 g/dl, haematological 
malignancy, anti-fibrinolytic use, cell saver blood returned to patient, lowest temperature intra- operative, previous cardiac surgery, pre-
operative Hb (g/dL) emergency surgery, CPB duration, operation duration, type of surgery, FFP and platelet transfusion during surgery, 
liver cirrhosis, preoperative circulation arrest, number of coronaries affected, age, sex, creatinine clearance, NYHA class, left ventricle 
hypertrophy, respiratory failure, smoking, Atrial fibrillation, endocarditis, hypertension, COPD, diabetes, vascular disease, preoperative 



























category  decrease  < 7 g/dL (crude)  value (adjusted)   
  ≥ 50%        
1 (ref) 9672 − − 1   1   
2 363 − + 1.28 1.16‐1.42 <0.001 0.93 0.82‐1.06 0.309
3 597 + − 1.08 0.99‐1.17 0.064 1.26 1.13‐1.41 <0.001
4 876 + + 1.65 1.55‐1.75 <0.001 1.12 1.02‐1.22 0.017
*  Adjusted for acetylsalicylic acid, clopidogrel and anticoagulant drug use, preoperative fibrinogen of less than 2 g/dL, hematological
malignancy, antifibrinolytic use, cell‐saver blood returned to patient, lowest temperature intraoperative, previous cardiac surgery, 
preoperative Hb (g/dL), emergency surgery, CPB duration, operation duration, type of surgery, FFP and PLT transfusion during surgery,
liver cirrhosis, preoperative circulation arrest, number of coronaries affected, age, sex, creatinine clearance, NYHA class, left ventricle 
hypertrophy, respiratory failure, smoking, atrial fibrillation, endocarditis, hypertension, COPD, diabetes, vascular disease, preoperative 
myocardial infarction, and CPR 24 hours before surgery.
 
*Adjusted for acetylsalicylic acid, clopidogrel and anticoagulant drug use, preoperative fibrinogen of less than 
2 g/dL, hematologic malignancy, antifibrinolytic use, cell-saver blood returned to patient, lowest temperature 
intraoperative, previous cardiac surgery, preoperative Hb (g/dL), emergency surgery, CPB duration, operation 
duration, type of surgery, FFP and PLT transfusion during surgery, liver cirrhosis, preoperative circulation arrest, 
number of coronaries affected, age, sex, creatinine clearance, NYHA class, left ventricle hypertrophy, respiratory 
failure, smoking, atrial fibrillation, endocarditis, hypertension, COPD, diabetes, vascular disease, preoperative 
myocardial infarction, and CPR 24 hours before surgery.
* Adjusted for: acetylic salicylic acid, clopidogrel and anti-coagulant drug use, preoperative fibrinogen <2 g/dl, 
haematological malignancy, anti-fibrinolytic use, cell saver blood r turned to patient, lowest temperature intra- 
operative, prev ous cardiac surg ry, pre-operative Hb (g/dL) emergency surgery, CPB duration, operation duration, 
type of surgery, FFP and platelet transfusion during surgery, liver cirrhosis, preoperative circulation arrest, number 
of coronaries affected, age, sex, creatinine clearance, NYHA class, left ventricle hypertrophy, respiratory failure, 
smoking, Atrial fibrillation, endocarditis, hypertension, COPD, diabetes, vascular disease, preoperative myocardial 
infarction, CPR 24h before surgery.
Red cell transfusions
As shown in Table 1, 7.3 and 7.9% of patients in categories 1 and 3 received red blood cell 
transfusions though their nadir Hb remained higher than 7 g/dl. This is most often the result of 
clinical judgment by the attending physician or intraoperative events, which indicated the need 
of a blood transfusion despite the Hb level higher than the transfusion trigger of 7 g/dl. Table 3 
presents the association between RBC transfusions and the composite endpoint within each of the 
four categories of Hb decrease. In Category 1 where there was neither a Hb decrease of at least 50 
% nor a Hb level of less than 7 g/dL, the adjusted odds of acquiring the composite endpoint was 
Tolerance of intraoperative hemoglobin decrease during cardiac surgery
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Category 1 9672 703 (7.3) − − 2.67 2.50‐2.86 <0.001 1.26 1.17‐1.36 <0.001
Category 2 363 157 (43.3) − + 0.91 0.74‐1.11 0.348 0.57 0.42‐0.77 <0.001
Category 3 597 47 (7.9) + − 3.00 2.33‐3.86 <0.001 0.88 0.55‐1.41 0.590
Category 4 876 393 (44.9) + + 1.64 1.45‐1.84 <0.001 0.95 0.78‐1.16 0.618
 
* Adjusted for acetylsalicylic acid, clopidogrel and anticoagulant drug use, preoperative fibrinogen of less than 2 g/dL, hematologic
malignancy, antifibrinolytic use, cell‐saver blood returned to patient, lowest temperature intraoperative, previous cardiac surgery,
preoperative Hb (g/dL), emergency surgery, CPB duration, operation duration, type of surgery, FFP and PLT transfusion during surgery, 
liver cirrhosis, preoperative circulation arrest, number of coronaries affected, age, sex, creatinine clearance, NYHA class, left ventricle 
hypertrophy, respiratory failure, smoking, atrial fibrillation, endocarditis, hypertension, COPD, diabetes, vascular disease, preoperative 
myocardial infarction, and CPR 24 hours before surgery.
 
1.51 (95% CI, 1.38-1.66) in transfused patients compared with non-transfused patients. In patients 
from Categories 2 and 4, 43.3 and 44.9% received red cell transfusions. Among these patients 
transfusion was associated with a decreased odds of developing the composite endpoint (aOR 
0.57, 95% CI 0.42-0.77, for Category 2; and aOR 0.95, 95% CI 0.78-1.16 for Category 4).
Among patients who had a Hb decrease of more than 50% but had an intraoperative nadir Hb of 
more than 7 g/dL, 47 (7.9%) patients received RBC transfusions. Among these patients transfusion 
was associated with a nonsignificant lower odds of developing composite endpoints (aOR, 0.88; 
95% CI, 0.55-1.41).
* Adjusted for cetylsalicylic acid, clopid grel and anticoagulant drug use, preoperative fibrinogen of less than 
2 g/dL, hematologic malignancy, antifibrinolytic use, cell-saver blood returned to patient, lowest temperature 
intraoperative, previous cardiac surgery, preoperative Hb (g/dL), emergency surgery, CPB duration, operation 
duration, type of surgery, FFP and PLT transfusion during surgery, liver cirrhosis, preoperative circulation arrest, 
number of coronaries affected, age, sex, creatinine clearance, NYHA class, left ventricle hypertrophy, respiratory 
failure, smoking, atrial fibrillation, endocarditis, hypertension, COPD, diabetes, vascular disease, preoperative 
myocardial infarction, and CPR 24 hours before surgery.
Discussion
In our cohort of cardiothoracic surgery patients an intraoperative Hb decrease of 50% or more was 
associated with a higher incidence of postoperative complications including in-hospital mortality 
and/or stroke and/or kidney failure and/or myocardial infarction, even if their Hb concentration 
remained higher than 7 g/dL. Males with higher preoperative Hb were overrepresented in this 
category , but when the analysis  was stratified for gender these findings also applied to females 
with a higher preoperative Hb.
This finding is in agreement with a previous study performed by Karkouti and colleagues who 
analyzed the degree of acute anemia that patients can safely tolerate during cardiac surgery.7 
That study also showed that a Hb decrease of more than 50% during surgery was associated 
with in-hospital mortality, stroke and kidney failure (OR 1.53, 95% CI, 1.12-2.08).7 In this study 
we combined two cut-off points creating four categories. This way we were able to analyze the 
association between absolute and relative Hb loss in more detail. We chose a broader definition 
of the composite endpoint; in addition to in-hospital mortality and/or stroke and/or renal failure 
our endpoint also comprised postoperative myocardial infarction.
Approximately 8% of the patients with more than 50% Hb loss were transfused RBCs despite Hb 
levels above 7 g/dL. In these patients, as well in patients who reached a nadir Hb below 7g/dL, 
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transfusion was associated with fewer postoperative complications, suggesting that transfusion 
might be efficacious in these patients. Yet, given the limited number of transfused patients in 
this subgroup and the lack of statistical significance, these findings have to be interpreted with 
caution.
To appreciate these findings, some issues need to be discussed. One of the strengths of our study 
was the large number of consecutive patients.  The outcome variables of all patients were known 
and therefore selection bias was avoided. Also, due to the large amount of detailed covariates we 
were able to correct thoroughly for possible confounding caused by differences in preoperative 
patient characteristics. While seeking causal inferences between exposure and outcome, we 
chose to adjust for risk factors for the outcome and differences in baseline patient characteristics 
independent of their significance.12
A limitation of our study was that we only took intra-operative Hb and transfusion into  account; 
this does not allow us to convey the conclusions to the whole perioperative period. The 
complexity of unravelling whether the complications that occur after cardiac surgery are caused 
by blood loss or by the events leading to excessive blood loss is well recognized. Although we 
tried to be as thorough as possible (for instance, by excluding re- sternotomies from our analysis) 
we cannot distinguish between the cause of Hb loss more than 50% and the acute anemia itself 
to explain the increased risk for the composite endpoint in this category.
A further limitation is that the number and timing of Hb measurements during surgery were 
not documented (besides the four standard measurements). Additional Hb measurements were 
performed on request by the attending anesthesiologist when deemed needed. This meant that 
the ‘correct’ lowest intraoperative Hb level might have been missed and that patients could have 
been misclassified. The risk of missing the ‘correct’ nadir Hb is a general problem in this type of 
study, since continuous measurement of Hb is not accurate enough for clinical use, especially in 
patients who have a low perfusion state.16,17
Our findings are biologically plausible, because it is known that an acute decrease in Hb level 
could have adverse consequences on end-organ function, especially on oxygen dependent 
organs as the kidney, heart and brain.18
An acute reduction in Hb level will be sensed on a cellular level which leads to adaptive 
cardiovascular and respiratory responses to optimize tissue oxygen delivery.13,18–21 These adaptive 
responses include an increase in cardiac output, a reduction in systemic vascular resistance with 
organ specific vasodilatation, and an increase in tissue oxygen extraction.18 Although these 
adaptive mechanisms can keep homeostatic balance intact for some time, depending on the 
extent and timing of Hb loss adaptive mechanisms may fail and eventually lead to end-organ 
damage.
The amount of Hb decrease that can be safely tolerated is highly debated. As long as  cellular 
oxygen content measurements cannot be applied routinely to define whether or not a RBC 
transfusion is indicated, it is of great importance to define the most beneficial transfusion policy. 
In critically ill patients and in patients undergoing cardiothoracic surgery, a restrictive transfusion 
strategy is propagated, with the purpose of reducing the risks associated with the (inappropriate) 
transfusion of RBCs, as those risks are well put forward in literature.22–25
Interestingly, a pilot trial in patients with symptomatic coronary artery disease, comparing 
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a restrictive (8 g/dL) versus a liberal (10 g/dL) transfusion threshold, showed that the liberal 
transfusion strategy was associated with a trend for fewer major cardiac events and deaths.26 
This underscores that the optimal transfusion threshold depends on the clinical situation and 
therefore differs for individual patients, which is corroborated by the results of an international 
forum in which 38 hospitals answered a questionnaire regarding their transfusion triggers 
and the use of guidelines. In those hospitals, target Hb on CPB differed, ranging from 6.0 till 
8.0 g/dL.25,27,28
Also the appropriate acceptable amount of hemodilution is uncertain. Several studies have 
addressed the adverse effects of a low nadir Hct.29–31 But if and when exactly volume and/or Hb 
replacement during cardiac surgery is indicated needs to be addressed in future studies.18,32
The results of our study imply that a fixed transfusion trigger might not be in the best interest 
of patients with a ‘higher’ preoperative Hb. Patients with a high preoperative Hb level must 
lose a greater Hb volume before reaching the transfusion triggers currently described in the 
guidelines.9,10 Therefore, these patients are more likely to suffer from anemia-related complications. 
It is unknown whether RBC transfusions decrease the risk of anemia-related complications in 
patients with an intraoperative Hb decrease of 50% or more. In our study we found that RBC 
transfusions were associated with a lower incidence of the composite endpoint in patients with a 
Hb decrease of 50% while their nadir Hb remained higher than 7 g/dL. The previously mentioned 
questionnaire shows that the transfusion threshold described in guidelines or local protocols is 
not the leading reason for transfusions, as additional variables also serve as important triggers.28 
Taken into account the results of our study, a Hb decrease of 50% or more poses one of these 
additional variables.
In conclusion, patients with an intraoperative Hb decrease of 50% or more may suffer from 
anemia-related complications even if their Hb remains higher than 7 g/dL.
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Intraoperative anemia and single red 
blood cell transfusion during cardiac 
surgery: An assessment of postoperative 
outcome including patients refusing 
blood transfusion
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Increasing evidence suggests benefits from restrictive red blood cell transfusion (RBC) thresholds 
in major surgery and critically ill patients. However, these benefits are not obvious in cardiac 
surgery patients with intraoperative anemia. The authors examined the association between 
uncorrected hemoglobin (Hb) levels and selected postoperative outcomes as well as the effects 
of RBCs.
Design
Cohort study with prospectively collected data from a cardiac surgery registry.
Setting
A major cardiac surgical hospital within the Netherlands, which is also a referral center for 
Jehovah’s Witnesses.
Participants
Patients (23,860) undergoing cardiac surgery between 1997 and 2013.
Interventions
Comparisons were done in patients with intraoperative nadir Hb of 8 g/dL and/or an Hb decrease 
> 50%. Comparison (A) between Jehovah’s Witnesses (Witnesses) and matched non-Jehovah’s 
Witnesses (non- Witnesses) transfused with 1 unit of RBC, and comparison (B) between patients 
given1unit of RBC intraoperatively versus matched non-transfused patients.
Measurements and Main Results
Postoperative outcomes were myocardial infarction, renal replacement therapy, stroke, and 
death. With propensity matching, the authors optimized exchangeability of the compared 
groups. Adverse outcomes increased with a decreasing Hb both among Witnesses and among 
non-Witnesses. The incidence of postoperative complications did not differ between Witnesses 
and matched non-Witnesses who received RBC (adjusted odds ratio1.44, 95% confidence interval 
0.63- 3.29). Similarly, postoperative complications did not differ between patients who received a 
red cell transfusion and matched patients who did not (adjusted odds ratio 0.94, 95% confidence 
interval 0.72-1.23).
Conclusion
Intraoperative anemia is associated with adverse outcomes after cardiac surgery, and a single RBC 
transfusion does not seem to influence these outcomes
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Intraoperative Anemia and Single Red Blood Cell Transfusion During Cardiac Surgery
Introduction
Both low intraoperative hemoglobin (Hb) concentration and red blood cell (RBC) transfusions 
have been associated with adverse outcomes after cardiac surgery.1–4 Results from randomized 
controlled trials performed in patients with various medical conditions, usually using 7.0 or 8.0 g/dL 
as a restrictive transfusion threshold, suggested no beneficial effects of a more liberal transfusion 
strategy.5–7 Clinical guidelines increasingly promote lower transfusion triggers despite insufficient 
evidence in cardiac surgery regarding the intraoperative Hb level at which the beneficial effects 
of RBC transfusions outweigh the risks.8–13
The interpretation of the association between Hb concentrations and clinical outcomes is 
hampered by the effect of RBC transfusions, since with decreasing Hb concentrations more 
patients will be treated with transfusions. RCTs cannot investigate this topic in severely anemic 
patients as withholding transfusion in these patients is widely considered unethical. Patients who 
decline transfusion for whatever reason (for example Jehovah’s Witnesses, further abbreviated 
as Witnesses) enable clinicians to study the association between Hb decrease and relevant 
postoperative outcomes in the absence of RBC transfusions. Comparing anemic Witnesses with 
transfused anemic non-Jehovah’s Witnesses (non-Witnesses) undergoing cardiac surgery can 
provide valuable information about the consequences of uncorrected anemia or the benefits of 
transfusion.
Previous studies with Witnesses showed an increase in morbidity when the Hb level decreased 
below 8g/dL, and an increased mortality when the Hb level decreased below 7 g/dL.4,14 However, 
cardiac surgery was not specially addressed in these studies. Cardiac surgery studies including 
Witnesses underscored the good outcome and similar mortality and morbidity rates as in non-
Witnesses, provided Hb levels were optimized.15–17
However, the postoperative outcomes of Witnesses undergoing cardiac surgery and suffering 
from an intraoperative Hb decrease below 8 g/dL (and thus reaching a possible harmful Hb 
level) have not been reported. The authors hypothesized that uncorrected anemia would lead 
to more postoperative complications and that RBC transfusions would help decrease these 
complications. The authors’ objectives were to describe the association between intraoperative 
Hb and postoperative adverse events among patients who received no RBC transfusions during 
cardiac surgery in both Witnesses and non-Witnesses. Furthermore, Witnesses who, based on 
intraoperative anemia (intraoperative nadir Hb <8 g/dL and/or Hb decrease >50%), would be 
eligible for RBC transfusion were compared to similar anemic non-Witnesses who received a single 
RBC transfusion. Because unidentified differences in preoperative selection and intraoperative 
treatment between Witnesses and non- Witnesses may have occurred, the authors composed 
an additional (non-Witness only) study cohort of anemic patients in which they compared non-
transfused patients with patients who received 1 unit of RBC.
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Methods of Study and Design
This study complied with the Declaration of Helsinki (10th version, 2012-2013). The local research 
ethics committee approved this study, and the need for informed consent was waived.
Study Setting
The analyses were performed with data of a single-center cardiac surgery registry. Details of this 
registry have been described earlier.13 In this registry, perioperative data, including morbidity 
and process as well as outcome indicators, from all consecutive patients who undergo cardiac 
surgery in the Amphia Hospital, Breda, the Netherlands are collected.  Data collection for the 
present analysis took place between January 1, 1997 and January 1, 2013 and was compliant 
with the Dutch National Cardiac Surgery Registry (BHN) and the Dutch National Intensive Care 
Registry (NICE, instituted since 1996).18 All data were acquired from preoperative, intraoperative, 
and postoperative routine blood collections and medical files. Data regarding blood transfusion 
were obtained from the hospital laboratory information system.
Since 2006, a Patient Blood Management Program (PBMP) is in place covering the complete 
perioperative period (including ICU and ward). This PBMP is compliant with the transfusion 
guidelines of the American Society of Anesthesiologists, the Dutch transfusion guidelines and, 
more specifically, the guidelines from the Society of Thoracic Surgeons and the Society of 
Cardiovascular Anesthesiologists (STS and SCA guidelines published in 2006 and updated in 
2011).19–21 Intraoperatively, an Hb trigger of 8.0g/dL is used. During cardiopulmonary bypass, 
Hb above 7.0 g/L is maintained either by transfusion or hemoconcentration, whatever is most 
appropriate according to the attending anesthesiologist.
Since 2009, this PBMP was further expanded with more elaborated coagulation monitoring and 
component therapy (Point-of-Care Coagulation, Rotem ®, TEM, Inc.). Within the Netherlands, the 
Amphia Hospital is a major referral center for Witnesses undergoing cardiac surgery. Witnesses 
are operated according to a local protocol prohibiting any transfusion of blood products. The 
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Study Population
To study the association between intraoperative Hb and adverse postoperative outcomes, all 
patients who underwent cardiac surgery between 1997 and 2013 (Witnesses and non-Witnesses) 
were included.
To assess the possible effect of RBC transfusion on postoperative outcome, the authors performed 
2 separate analyses. First, they compared Witnesses with transfused non-Witnesses (Comparison 
A); second, they compared transfused with non-transfused non-Witnesses in a different study 
cohort (Comparison B).
Comparison A
All anemic Witnesses who, according to current guidelines, could have benefitted from 
intraoperative RBC transfusion were identified. For that purpose the authors defined anemia as 
an intraoperative Hb < 8 g/dL and/or an Hb decrease > 50%. The authors chose this double 
threshold based on current literature and because a previous study of their research group 
showed that patients who had an Hb decrease of 50% or more had a significantly higher chance 
of adverse outcome. The authors assumed that patients with an intraoperative Hb decrease of 
> 50% would equally benefit from an RBC transfusion as patients with an Hb level below 8 g/
dL.13 Witnesses were matched to non-Witnesses who received 1 RBC unit intraoperatively. The 
authors selected patients who received 1 RBC unit because comparability between patients 
who receive none and patients who receive multiple RBC is poor. To prevent selection bias, all 
non-Witnesses receiving a single RBC were considered possible matches regardless of whether 
they had received platelet/FFP transfusion or not. If the authors only included non-Witnesses 
who had received one RBC and no other blood products, they would have ignored the fact that 
Witnesses also could have been in need of a transfusion with additional blood products. Since the 
introduction of the PBMP in 2006, basic intraoperative blood- sparing measures in non-Witnesses 
have become similar to those in Witnesses. However, the authors acknowledge that Witnesses 
may undergo a more careful preoperative selection and preparation while, intraoperatively and 
postoperatively, the cardiac surgical team may work more cautiously to limit blood loss. This may 
introduce bias or other unidentified benefits that compromises the comparability of Witnesses 
and non-Witnesses.15–17,22–24
Comparison B
In order to cope with these identified and unidentified biases when comparing Witnesses, the 
authors designed an additional comparison of non-Witnesses. Here, the authors compared non- 
transfused patients with propensity- matched patients who received a single intraoperative 
RBC transfusion in the absence of any additional blood products (because in this cohort this 
would not introduce a selection bias). Data were available on whether the RBC transfusions had 
been administered during surgery, in the ICU, or on the surgical ward. This information, however, 
did not allow a distinction between intraoperative RBC transfusion during the primary cardiac 
operation and a possible subsequent re-sternotomy. The authors, therefore, excluded patients 
who had undergone a resternotomy.
Intraoperative Anemia and Single Red Blood Cell Transfusion During Cardiac Surgery
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Exposure and Outcome Definitions
The lowest intraoperative Hb was taken as the nadir Hb. The Hb decrease in percent was calculated 
as follows: [(preoperative Hb - nadir Hb) / preoperative Hb] x 100. Intraoperative Hb was measured 
routinely according to institution protocol after induction of anesthesia, 30 minutes after the 
start of cardiopulmonary bypass (CPB), after cardioplegia, and after heparin reversal before chest 
closure. Additional Hb measurements were left to the discretion of the attending anesthesiologist 
and perfusionist.
The postoperative outcomes of interest were myocardial infarction, acute kidney injury, stroke, 
ICU length of stay, duration of postoperative mechanical ventilation, in-hospital mortality, and a 
composite endpoint of serious adverse outcomes consisting of myocardial infarction, the need 
for renal replacement therapy, stroke, and in hospital mortality.
The diagnosis of postoperative myocardial infarction was made based upon either the occurrence 
of new Q waves on the electrocardiogram (ECG) or new ischemic ST changes in combination 
with abnormal postoperative troponin T levels (troponin T level 40.5 m/L for CABG surgery, 
troponin T level 40.8 m/L for valve surgery, and troponin T level above 1.0 m/L for combined CABG 
and valve procedures). Both serum creatinine and troponin T were measured routinely in every 
patient postoperatively. Acute kidney failure was defined as the need for postoperative renal 
replacement therapy excluding patients on preoperative renal dialysis or replacement therapy 
and/or a rise in serum creatinine of more than 100% as compared to preoperative creatinine. 
Stroke was defined as a new cerebrovascular event leading to neurologic deficit lasting at least 
24 hours and diagnosed by a neurologist. ICU length of stay (ICU LOS) as well as mechanical 
ventilation time were measured in hours.
Statistical Analyses
To describe the association between the intraoperative nadir Hb and postoperative adverse 
outcome for all Witnesses as well as for all non-Witnesses who had not received RBC transfusions, 
the nadir Hb was categorized and plotted against the composite endpoint. No significance 
tests were performed because the authors studied the trend in decreasing Hb in relation to the 
composite endpoint and did not use a specific cut-off value.
To analyze the effect of a single unit of RBC transfused during surgery on postoperative adverse 
outcomes, all Witnesses who reached an intraoperative nadir Hb < 8 g/dL and/or an intraoperative 
Hb decrease > 50% were selected and propensity matched 1:1 with non-Witnesses who received 
1unit of red cells (Comparison A). Also, all non-Witnesses who had an intraoperative nadir Hb < 8 
g/dL and/or an intraoperative Hb decrease > 50% and who received 1 unit of RBC during surgery 
(and no other blood products) were identified. These patients were propensity matched 1:1 with 
non-Witnesses who did not receive any blood products (Comparison B).
The propensity score for comparison A was developed for matching Witnesses to non-Witnesses 
who received one unit of RBC. The propensity score for comparison B was developed to match 
anemic non-Witnesses who were not transfused with anemic non-Witnesses who received one 
RBC during surgery. The propensity scores were composed using binary regression modeling and 
included 37 variables. The matching technique used was nearest neighbor.
Chapter 4
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Figure 1: Distribution of intraoperative nadir Hb (g/dL) in the total Witnesses population (n = 270) in relation to the composite endpoint. 
 
In addition to propensity score matching, the authors performed a multi variable analysis adjusting 
for variables, which were distributed unequally between transfused and non- transfused patients, 
using binary logistic regression modeling.
Results
Patient Characteristics
A total of 23,860 consecutive patients were included during a study period of 15 years, of whom 
270 patients were Witnesses. Among the Witnesses, 79 (29%) patients were female, and the 
median age was 68 (interquartile range [IQR] 60-74) years. Most of these patients underwent 
an isolated CABG (65%). The median EuroSCORE I was 5 (IQR3-7). In total, 48 (18%) of the 
Witnesses and 17% of the non-transfused, non-Witnesses developed the composite endpoint 
complications. Intraoperative nadir Hb concentration in relation to the composite endpoint in 
Witnesses is shown in Figure 1.
Figure 1. Distribution of intraoperative nadir Hb (g/dL) in the total Witnesses population (n = 270) in relation to 
the composite endpoint.
Postoperative complications increase with decreasing intraoperative Hb concentrations. The 
largest increase in incidence of the composite endpoint was seen when the nadir Hb decreased 
below 8 g/dL. Among Witnesses with a nadir Hb below 8 g/dL, the composite endpoint was seen 
in 24% of the patients. In non-Witness patients who did not receive transfusions the association 
between Hb and clinical outcomes showed a similar pattern. Among this group of patients with 
a nadir Hb below 8 g/dL, the composite endpoint was seen in 21% of the patients (Figure 2).
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Figure 2: Distribution of intra-operative nadir Hb (g/dL) in the non-transfused non-JW population (n=20207) in relation to the composite endpoint. 
 
Figure 2. Distribution of intra-operative nadir Hb (g/dL) in the non-transfused non-JW population (n=20207) in 
relation to the composite endpoint.
Clinical Outcomes in Anemic Witnesses Compared to Transfused Anemic Non-Witnesses 
(Comparison A)
Figure 3 presents the flow chart of patient exclusions and number of patients available for this 
analysis. A total of 61 Witnesses with an intraoperative Hb level <8 g/dL and/or an Hb decrease 
>50% were matched with non-Witness patients who had received 1 unit of red cells.
Perioperative characteristics of these matched patients are shown in Table 1. The comorbidities, 
demographics, and risk factors between Witnesses and non-Witnesses largely were similar. After 
matching, slight differences were found; for example, in age and gender.
Propensity scores were similar in both groups. About a third of the non-Witnesses transfused with 
1 unit of RBC received additional blood products; 33% received fresh frozen plasma (FFP), and 
31% received additional platelet concentrates. The intraoperative nadir Hb was slightly higher 
among the Witnesses than among the other patients. Witnesses had a median Hb of 7.6 g/dL (IQR 
7.2 - 7.9 g/dL), and non-Witnesses had a median Hb of 7.3 (IQR 6.6 - 7.6 g/dL). Table 2 presents 
postoperative outcomes. Witnesses and non-Witnesses had similar composite outcomes. 
Furthermore, Witnesses required a shorter mechanical ventilation time. Witnesses: median 11 h 
IQR 8-22; non- Witnesses: median 17 h IQR 10-30, p value 0.024.
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Figure 3. flowchart of patient exclusions and number of JW available for analysis
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Table 1: Characteristics of patients with an intraoperative Hb < 8 g/dL and/or an intraoperative Hb 
















Propensity score, median (IQR) 0.0164(0.0078-0.0292) 0.0164(0.0076-0.0293) 0.0164(0.0076-0.0292) 
Age, median (IQR)  67(61-75)  64(57-73)  68(64-85) 
Female, N (%)   66(54.1)   28(45.9)   38(62.3) 
Weight (kg), median (IQR)  75(65-85)  78(67-86)  73(65-85) 
Year of surgery, median (IQR) 2002(1998-2004) 2002(1998-2004) 2001(1998-2005) 
Previous cardiac surgery, N (%)    11(9.0)   5(8.2)   6(9.8) 
Smoking, N (%)     9(7.4)   5(8.2)   4(6.6) 
Pre-operative Hb level, g/dl, median (IQR) 14.2(13.2-14.9) 14.5(13.4-15.1) 13.7( 13.0-14.5) 
Hypercholesterolemia, N (%)   72(59.0)   35(57.4)    37(60.7) 
Creatinine, median (IQR)  87(70-99)  86(73-95)  88(69-101) 
Vascular disease, N (%)   18(14.8)   7(11.5)    11(18.0) 
Left ventricle hypertrophy, N (%) 34(27.9) 17(27.9) 17(27.9) 
Atrial fibrillation, N (%)  12(9.8)  6(9.8)  6(9.8) 
Hypertension, N (%) 57(46.7) 29(47.5) 28(45.9) 
COPD, N (%) 18(14.8) 7(11.5) 11(18.0) 
Diabetes, N (%) 
- type I 11(9.0) 4(6.6) 7(11.5) 
- type II 16(13.1) 7(11.5) 9(14.8) 
n. coronary arteries affected, median (IQR) 3(0-3) 3(0-3) 3(0-3) 
> 50% LAD occlusion, N (%)                                                                      16(13.1)                                   8(13.1)                                    8(13.1) 
Myocardial infarction, N (%)                                                                       27(22.1)                                  14(23.0)                                  13(21.3) 
Ejection Fraction, N (%) 
- good 94(77.0) 48(78.7) 46(75.4) 
- moderately depressed 16(13.1) 9(14.8) 7(11.5) 
- severely depressed   8(6.6)   3(4.9)  5(8.2) 
Aortic valve disease, N (%) 42(34.4) 22(36.1) 20(32.8) 
Mitral valve disease, N (%) 22(18.0) 11(18.0) 11(18.0) 
NYHA class IV, N (%)   8(6.6)   3(4.9)  5(8.2) 
Cardiovascular insufficiency,* N (%) 19(15.6)  9(14.8) 10(16.4) 
Respiratory insufficiency,† N (%)   2(1.6)   1(1.6)  1(1.6) 
Aspirin use, N (%) 58(47.5) 32(52.5) 26(42.6) 
Clopidogrel use, N (%)  3(2.50   2(3.3)  1(1.6) 
Anti-coagulant drug use,‡ N (%) 22(18.0) 13(21.3)  9(14.8) 
Calcium antagonist use, N (%) 58(47.5) 29(47.5) 29(47.5) 
Beta blocker use, N (%) 82(67.2) 44(72.1) 38(62.3) 
Nitrate use, N (%) 62(50.8) 31(50.8) 31(50.8) 
Inotropic drug use, N (%)   1(0.8)   1(1.6)   0(0) 
Emergency surgery, N (%)   4(3.3)   3(4.9)  1(1.6) 
Type of Surgery, N (%) 
- CABG 62(50.8) 32(52.5) 30(49.2) 
- CABG + valve 23(18.9) 11(18.0) 12(19.7) 
- CABG + other 0(0) 0(0) 0(0) 
- Valve 24(19.7) 13(21.3) 11(18.0) 
- Other 13(10.7)  5(8.2) 8(13.1) 
EuroSCORE I, median (IQR)   5(4-7) 5(2-7)  6(4-7) 
 
Intra-operative variables 
Time in Surgery (min), median (IQR) 283(250-332) 283(245-321) 282(253-347) 
CPB duration (min), median (IQR)  124(99-165) 123(102-158)  125(94-182) 
Intra-operative circulatory arrest, N (%)     7(5.7)  2(3.3)   5(8.2) 
Cellsaver blood returned during surgery, N (%)   34(27.9)     20(32.8)     14(23.0) 
Intra-operative nadir Hb (g/dL), median (IQR)  7.4(6.9-7.8)  7.6(7.2-7.9)  7.3(6.6-7.6) 
Intra-operative nadir Hb < 8 g/dL, N (%)  120(98.4)     59(96.7)     61(100) 
Hb decrease > 50%, N (%)                                                                         37(30.3)                                  18(29.5)                                  19(31.1)  
FFP transfusion during surgery, N (%)                                                       20(16.4)                                     0(0)                                     20(32.8) 
Platelet transfusion during surgery, N (%)                                                          19(15.6)                                        0(0)                                             19(31.1)  
Lowest temperature in surgery (C), median (IQR)                                  30.3(29.0-33.2)                             31(30-34)                                30(28-32)                              
*Defined as: NYHA class IV and/or preoperative nitrate i.v and/or heparin i.v. and/or IABP 
†    Defined as the need for mechanical ventilation 
‡    Defined as the use of heparin, low molecular weight heparin, coumarines or a combination* Defined as: NYHA class IV and/or preoperative nitrate i.v and/or heparin i.v. and/or IABP
† Defined as the need for mechanical ventilation
‡ Defined as the use of heparin, low molecular weight heparin, coumarines or a combination
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Table 2: Postoperative Outcomes in patients with an intra-operative nadir Hb < 8 g/dL and or an intra- 





















Myocardial infarction, N (%) 12(19.7) 13(21.3) 1.11(0.46-2.67) 1.18(0.47-2.96) 
Acute kidney injury, N (%) 5(8.2) 6(9.8) 1.22(0.35-4.24) 0.77(0.19-3.06) 
CVVH de novo, N (%) 2(3.3) 6(9.8) 3.22(0.62-16.62) 3.68(0.69-19.73) 
Stroke, N (%) 2(3.3) 2(3.3) 1.00(0.14-7.34) 0.83(0.10-7.03) 
ICU length of stay (hours), median (IQR) 24(22-58) 48(23-91)   
ICU length of stay > 48 hours, N (%) 22(36.1) 30(49.2) 1.72(0.83-3.54) 1.89(0.88-4.06) 
Mechanical ventilation time (hours), median (IQR) 11(8-22) 17(10-30)   
Mechanical ventilation > 24 hours, N (%) 11(18.0) 19(31.1) 2.06(0.88-4.80) 2.13(0.88-5.16) 
In hospital mortality, N (%) 1(1.6) 2(3.3) 2.03(0.18-23.0) 0.81(0.05-13.51) 
Hb level at discharge (g/dL), median (IQR) 10.8(10.4-11.3) 10.6(10.0-10.8)   
Composite endpoint,† N (%) 15(24.6) 20(32.8) 1.50(0.68-3.30) 1.44(0.63-3.29) 
 
*  Adjusted for: intra-operative nadir Hb (g/dL) 
† Composite endpoint consisting of: Myocardial infarction, CVVH, Stroke, in hospital mortality 
 
Transfusions and Clinical Outcomes in Anemic Non- Witnesses (Comparison B)
A total of 831 non-Witnesses with an intraoperative Hb <8 g/dL and/or an Hb decrease >50% 
who received 1 RBC and no other blood products were matched with the same number of 
patients who received no blood products. Figure 4 presents the flow chart of patient exclusions 
and number of patients available for analysis. Perioperative characteristics of these patients are 
shown in Table 3. Table 4 shows the postoperative outcomes of the selected non-Witnesses. 
After reviewing baseline characteristics, additional adjustment was made with regard to time in 
surgery (min), time on CPB (min), intra-operative circulatory arrest (min), cell-saver blood returned 
during surge as a binary variable), and intraoperative nadir Hb (g/dL) in the multivariable analysis. 
The composite endpoint was seen in 149 non-transfused patients (18%) and in 144 transfused 
patients (17%) (aOR 0.94, CI 0.72-1.23).
* Adjusted for: intra-operative nadir Hb (g/dL)
† Composite endpoint consisting of: Myocardial infarction, CVVH, Stroke, in hospital mortality
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Figure 4: Flow chart of patient exclusions and number of non-JW transfused with one RBC available for analysis 
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Table 3: Patient Characteristics in patients with an intra-operative Hb < 8 g/dL and/or a intra-operative Hb 










(N=1662) (N=831) (N=831) 
Propensity score, median (IQR) 0.2653(0.1630-0.3966) 0.2654(0.1629-0.3967) 0.2653(0.1630-3966) 
Age, median (IQR)   72(65-77)  72(65-77)  72(65-77) 
Female, N (%)  1075(64.7)  537(64.6)  538(64.7) 
Weight (kg), median (IQR)   71(63-80)  71(64-80)  70(63-80) 
Year of surgery, median (IQR) 2005(2002-2008) 2005(2002-2008) 2005(2001-2009) 
Previous cardiac surgery, N (%)  127(7.6)  65(7.8)  62(7.5) 
Smoking, N (%) 236(14.2) 123(14.8) 113(13.6) 
Pre-operative Hb level, g/dl, median (IQR) 12.6(11.8-13.4) 12.6(11.8-13.4) 12.6(11.8-13.4) 
Hypercholesterolemia, N (%)   1049(63.1)   521(62.7)   528(63.5) 
Creatinine, median (IQR)  84(71-102)  82(70-102)  85(72-103) 
Vascular disease, N (%)   305(18.4)   150(18.1)   155(18.7) 
Left ventricle hypertrophy, N (%)   466(28.0)   232(27.9)   234(28.2) 
Atrial fibrillation, N (%)   218(13.1)   108(13.0)   110(13.2) 
Hypertension, N (%)   979(58.9)   487(58.6)   492(59.2) 
COPD, N (%)   306(18.4)   151(18.2)   155(18.7) 
Diabetes, N (%) 
- type I 75(4.5) 35(4.2) 40(4.8) 
- type II 326(19.6) 160(19.3) 166(20.0) 
n. coronary arteries affected, median (IQR) 3(0-3) 3(0-3) 3(1-3) 
> 50% LAD occlusion, N (%)                                                                    272(16.4)                                 143(17.2)                                129(15.5) 
Myocardial infarction, N (%)                                                                     596(35.9)                                 289(34.8)                                307(36.9) 
Ejection Fraction, N (%) 
- good 1215(73.1) 615(74.0) 600(72.2) 
- moderately depressed 302(18.2) 142(17.1) 160(19.3) 
- severely depressed  147(8.8)  74(8.9)   73(8.8) 
Aortic valve disease, N (%) 510(30.7) 258(31.0) 252(30.3) 
Mitral valve disease, N (%) 407(24.5) 210(25.3) 197(23.7) 
NYHA class IV, N (%) 271(16.3) 130(15.6) 141(17.0) 
Cardiovascular insufficiency,* N (%)  345(20.8) 177(21.3) 168(20.2) 
Respiratory insufficiency,† N (%)   90(5.4)  41(4.9)   49(5.9) 
Aspirin use, N (%)  873(52.5) 440(52.9) 433(52.1) 
Clopidogrel use, N (%)  244(14.7) 113(13.6) 131(15.8) 
Anti-coagulant drug use,‡ N (%)  555(33.4) 272(32.7) 283(34.1) 
Calcium antagonist use, N (%)  492(29.6) 245(29.5) 247(29.7) 
Beta blocker use, N (%) 1218(73.3) 603(72.6) 615(74.0) 
Nitrate use, N (%)  600(36.1) 298(35.9) 302(36.3) 
Inotropic drug use, N (%)   45(2.7)  23(2.8)   22(2.6) 
Emergency surgery, N (%)  147(8.8)  81(9.7)   66(7.9) 
Type of Surgery, N (%) 
- CABG 956(57.5) 470(56.6) 486(58.5) 
- CABG + valve 290(17.4) 145(17.4) 145(17.4) 
- CABG + other 14(0.8) 8(1.0) 6(0.7) 
- Valve 355(21.4) 182(21.9) 173(20.8) 
- Other 46(2.8) 25(3.0) 21(2.5) 
EuroSCORE I, median (IQR)  6(4-9)  7(4-9)  6(4-9) 
 
Intra-operative variables 
Time in Surgery (min), median (IQR) 240(205-284) 235(201-275) 245(205-290) 
CPB duration (min), median (IQR)   99(78-128)   97(76-124)  101(80-131) 
Intra-operative circulatory arrest, N (%)  25(1.5)  16(1.9)   9(1.1) 
Cellsaver blood returned during surgery, N (%)    739(44.5)    364(43.8)   375(45.1) 
Intra-operative nadir Hb (g/dL), median (IQR)  7.2(6.8-7.6)  7.4(6.9-7.7)  7.1(6.4-7.6) 
Intra-operative nadir Hb < 8 g/dL, N (%)   1659(99.8)    828(99.6)   831(100.0) 
Hb decrease > 50%, N (%)    303(18.2)    102(12.3)   201(24.2) 
Lowest temperature in surgery (C), median (IQR)    34(32-34)    33(32-34)   34(32-35) 
 
* Defines as: NYHA class IV and/or preoperative nitrate i.v and/or heparin i.v. and/or IABP 
† Defined as the need for mechanical ventilation 
‡ Defined as the use of heparin, low molecular weight heparin, coumarines or a combination * Defines as: NYHA cla s IV and/or preope at ve nitrate i.v nd/ r heparin i.v. and/or IABP
† Defined as the need for mechanical ventilation
‡ Defined as the use of heparin, low molecular weight heparin, coumarines or a combination
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* Adjusted for: time in surgery, CPB duration, intra-operative circulatory arrest, cellsaver blood returned during 
surgery, intra-operative nadir Hb (g/dL)
† Composite endpoint consisting of: Myocardial infarction, CVVH, Stroke, in hospital mortality
Discussion
Main Findings
In both Witnesses and non-transfused non-Witnesses who underwent cardiac surgery, lower 
intraoperative Hb was associated with a higher incidence of adverse postoperative events. 
Postoperative outcomes of anemic Witnesses and matched non-Witnesses who had received, 
intraoperatively, 1 unit of RBC were similar, with the exception that Witnesses had a shorter 
duration of mechanical ventilation than the patients who received blood products. In order to 
cope with biases when comparing Witnesses, comparison B showed that postoperative outcome 
in transfused and non-transfused anemic non-Witnesses also revealed no differences.
Strengths and Limitations
Many studies have shown that Witnesses can safely undergo cardiac surgery. To the authors’ 
knowledge, however, this study is the first to focus on Witnesses with moderate-to-severe 
anemia by comparing anemic Witnesses with a matched group of anemic non-Witnesses who 
received, intraoperatively, 1 RBC. The authors’ study indirectly suggested that a single packed cell 
transfusion did not impact outcome in moderately severe anemia in cardiac surgery.
To appreciate the authors’ results, some issues need to be discussed. The authors examined 
anemia and the role of RBC on clinical endpoints using Witnesses as a non-transfused control 
group. Despite all the authors’ efforts, they cannot ensure the absence of residual confounding in 
their study as not all possible preoperative and intraoperative
variables were measured.25,26
Analyzing the postoperative outcomes of Jehovah’s witnesses was an important part of 
the authors’ study because Witnesses can provide valuable information about the course of 
uncorrected anemia. However, surgeons and anesthesiologists may work more cautiously during 
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Table 4: Postoperative Outcomes in patients with an intra-operative nadir Hb < 8 g/dL and or an intra- 





















Myocardial infarction, N (%)                                                                 83(10.0)                      88(10.6)                1.07(0.78-1.47)           1.03(0.74-1.42) 
Acute kidney injury, N (%)                                                                     64(7.7)                       84(10.1)                1.35(0.96-1.89)           1.29(0.91-1.84) 
CVVH de novo, N (%)                                                                           42(5.1)                        43(5.2)                 1.03(0.66-1.59)           0.89(0.56-1.40) 
Stroke, N (%)                                                                                         15(1.9)                        18(2.4)                 1.20(0.60-2.41)           1.33(0.65-2.68) 
ICU length of stay (hours), median (IQR)                                            24(20-48)                    24(21-63) 
ICU length of stay > 48 hours, N (%)                                                  206(24.8)                    233(28.0)               1.18(0.95-1.47)           1.14(0.91-1.43) 
Mechanical ventilation time (hours), median (IQR)                              10(7-14)                      10(7-16) 
Mechanical ventilation > 24 hours, N (%)                                             96(11.6)                     112(13.5)               1.19(0.89-1.60)           1.21(0.90-1.64) 
In hospital mortality, N (%)                                                                    30(3.6)                        20(2.4)                 0.66(0.37-1.17)           0.64(0.34-1.19) 
Hb level at discharge (g/dL), median (IQR)                                     10.0(9.3-10.8)            10.1(9.5-10.9) 
Composite endpoint†, N (%)                                                               149(17.9)                    144(17.3)               1.04(0.81-1.34)           0.94(0.72-1.23) 
 
*    Adjusted for: time in surgery, CPB duration, intra-operative circulatory arrest, cellsaver blood returned during surgery, intra-operative 
nadir Hb (g/dL) 
†  Composite endpoint consisting of: Myocardial infarction, CVVH, Stroke, in hospital mortality 
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surgery on Witnesses to limit blood loss and avoid a low Hb. This effect of caution during surgery 
could not be measured, and therefore the authors could not adjust for it. Additionally, Witnesses 
were compared to transfused patients who received 1 RBC. However, one-third of these non-
Witnesses received additional blood products during surgery, possibly influencing postoperative 
outcomes.27,28
In an attempt to rule out possible confounding associated with patient selection and surgical 
caution to prevent blood loss in Witnesses and to maximize comparability between patients 
who received an RBC transfusion and patients who did not, the authors performed analyses in 
an additional formed cohort comparing transfused non-Witnesses with non-transfused non-
Witnesses. This cohort included different patients and could not be compared with the cohort 
formed with Jehovah’s Witnesses. In these additional analyses, the authors compared non-
Witnesses receiving only 1 RBC intraoperatively (and no additional blood products) with non-
Witnesses receiving no blood products at all. While the 2 separate analyses cannot be compared 
with regard to absolute outcomes because both cohorts differed in baseline characteristics, both 
approaches failed to show any differences between transfused and non-transfused patients.
Because comparability between patients who received multiple RBC transfusions and patients 
who received no RBC transfusions was low, the authors chose to match non-transfused patients 
with patients who received only 1 RBC. This limited the generalizability of the authors’ findings 
to patients who received only 1 RBC intraoperatively. Another limitation of the authors’ study 
was that they ignored the duration of time each patient remained on their nadir Hb. The nadir 
Hb typically is reached during bypass. Besides transfusion, other measures may have been 
undertaken to restore oxygen delivery. As the authors did not measure the duration of anemia 
before treatment restored Hb, it might be speculated that the impact of anemia may not have 
been long enough to discriminate for the possibly beneficial effects of transfusion.
Comparison with Previous Studies
There was convincing evidence that bloodless cardiac surgery could be performed with results 
equivalent to cardiac surgery in (low-risk) non-Witnesses.15–17,22–24 The authors’ results showed 
that this was also true in Witnesses who experienced intra-operative moderate-to-severe anemia 
(nadir Hb level < 8 g/dL). Both in Witnesses and in non- Witnesses, the authors observed that a 
lower Hb level was associated with a higher incidence of the composite endpoint. This was in 
agreement with previous studies showing a significant association with morbidity and mortality,
especially when postoperative Hb levels decreased below 5-7.5 g/dL.11,29
The authors did not find a significant beneficial or adverse effect of 1 RBC transfusion. In previous 
studies, both beneficial and adverse effects of RBC transfusions in cardiac surgery patients have 
been reported.13,30–33
Several studies reported worse outcome in cardiac surgery patients who received 1 and 2 units 
of RBC; other studies, like a recently performed RCT, showed that restrictive transfusion regimens 
may increase cardiogenic shock.34–39 In the authors’ cohort, they observed that Witnesses had a 
shorter ventilation time when compared to non-Witnesses who received blood products. The 
same result has been found in several other studies.15 Whether this was due to blood products or 
due to another cause could not be concluded from the authors’ study.
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Clinical Implications
Perioperative anemia is associated with adverse outcomes after cardiac surgery. Previous studies 
have reported on the deleterious effect of anemia on end-organ function of organs that depend 
on a relatively high oxygen extraction ratio like the kidneys, the heart, and the brain.1,2,40 Treating 
or preventing anemia with RBC transfusions has its own merits. In literature, many adverse effects 
of RBC transfusions were described, varying from antibody formation to increased postoperative 
morbidity like cerebrovascular accidents and acute kidney injury. Keeping the above in mind, 
the authors formulated clinical endpoints assessing the effect of anemia on the function of end-
organ systems that are most dependent on sufficient oxygen delivery. Therefore, if any effects of 
anemia and/or RBC transfusion could be seen, the authors expected it to be seen in the endpoints 
formulated.
In this cardiac surgical population, including patients with moderate-to-severe blood loss, 
low intraoperative Hb is associated with more postoperative complications. The authors were 
reluctant to conclude that this may have consequences for settings of a transfusion threshold. 
They found a single RBC appeared not to affect postoperative outcomes.
The authors’ results could imply that in anemic patients, transfusion of a single unit of RBC 
generally would not affect postoperative outcome and potentially could be avoided. However, 
they could not exclude that in the individual patient transfusion could either be beneficial or 
disadvantageous. Whether or not this is the case depends on the clinical profile of the patient.10
In conclusion, in this cardiac surgical population, including patients with moderate-to-severe 
blood loss, low intraoperative Hb was associated with more postoperative complications, but 
transfusion of a single RBC appeared not to affect them.
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The formation of red blood cell (RBC) antibodies could be enhanced by the presence of 
inflammation caused by prolonged RBC storage, as was shown in animal studies. The low 
occurrence (<10%) of K-antigen in most populations often enables identification of the K+ RBC 
unit that triggered anti-K formation and determination of its storage time. This study aims to 
quantify the association of anti-K formation with RBC storage time.
Study designs and methods
K− patients who had not been previously transfused and received at least 1 K+ unit between 
January 2004 and August 2013 were identified. First, the influence of storage time of the K+ units 
was assessed as mean, maximum, and minimum storage times within one transfusion interval and 
at various cutoff points for old versus young blood (14, 18, and 21 days). Second, concomitantly 
transfused K− units were studied within different periods surrounding the K+ unit(s).
Results
Twenty-three patients formed anti-K, while 274 patients did not. The adjusted relative risks of 
anti-K formation for mean, maximum, and minimum storage time (days) ranged from 1.01 to 1.03 
(95% confidence interval, 0.96-1.08). When analyzing the association between only “younger” and 
only “older” K+ units at various cutoff points, no association was found. Similarly, no association 
was found between storage time of the concomitantly transfused K− units and anti-K formation.
Conclusion
Within the range of storage times used in normal clinical practice in the Netherlands, no 
association could be found between RBC storage time and anti-K formation.
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Introduction
The role of red blood cell (RBC) storage time on various (adverse) clinical outcomes in transfused 
patients is still elusive. Reports on an association between prolonged RBC storage and adverse 
clinical outcomes like a higher infection rate, prolonged hospital stay, or even mortality are 
conflicting.1–4
One of the most frequent adverse effects of RBC transfusions is the formation of alloantibodies 
against incompatible donor antigens. The consequences of these alloantibodies in transfusion 
medicine vary from logistic inconvenience finding compatible blood, to delayed and acute 
hemolytic reactions. Unraveling genetic and environmental, presumably pro-inflammatory, 
conditions enhancing RBC immunization is important to develop preventive strategies such as 
preemptive extended matching of RBC transfusions.5–7 In a mouse model, it has been demonstrated 
that leukoreduced RBCs stored for 14 days resulted in higher alloantibody levels compared to 
fresh RBCs.8 Two previous studies have addressed this subject in humans. Yazer and Triulzi found 
that multiple D+ units had the same mean storage time in patients who formed anti-D and 
in those who did not.9 Zalpuri and colleagues10 analyzed storage time on any immunization, 
without differentiating between antigen immunogenicity, and also found no association.10
However, a limitation of both of these studies is that it was not known which RBC unit actually 
triggered immunization. The relative low frequency (<10%) of the K blood group antigen in 
most ethnic populations reduces the likelihood that patients receive multiple K+ units during a 
transfusion event.11 Therefore, it is often possible to identify the K+ RBC unit that triggered an 
antibody response and to determine the storage time of this unit.
The primary objective of this study was to quantify the association between the storage time 
of K+ RBC and anti-K formation in a new user cohort. Furthermore, to elucidate a potential role 
of antibody formation stimulating or dampening factors possibly present in concomitantly 
transfused units, the association of the storage time of concomitantly transfused K− units with 
anti-K formation was also quantified in various periods surrounding the K+ transfusion event.
Materials and Methods
Data collection and patients
In this single center, new user cohort study, K− patients who received at least one K+ RBC unit 
with or without concomitantly transfused K− units were included. Patients were selected from 
the Leiden University Medical Center in Leiden, the Netherlands, from January 2004 until August 
2013. Data regarding age, sex, diagnosis, transfusion dates, and antibody follow-up were collected 
from hospital laboratory files. Donation dates and K blood group data of all transfused units were 
collected from the Dutch national blood bank (Sanquin Blood Supply) ePROGESA database (MAK-
System International Group).
RBC storage time was defined as the number of days between donation and transfusion, with the 
day of donation defined as Day 0. A transfusion event was defined as a 7-day period in which the 
patient received K+ RBCs with Day 0 defined as the day of the first K+ transfusion. Storage times 
of all K+ RBC units and all concomitantly transfused K− units in a period of 30 days preceding and 
up to 30 days following a K+ transfusion event were collected. Transfusions outside this period 
were not included for analysis.
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The antibody follow-up period started at the first K+ RBC transfusion and ended at seroconversion 
or at the last antibody test performed, which was always at least 30 days after the last K+ 
transfusion. In the Netherlands, women younger than 46 years and patients with congenital or 
acquired hemolytic disorders requiring regular transfusions routinely receive K-antigen (and c, E 
antigens) matched RBCs to reduce antibody formation.
Blood products
In the Netherlands, standard RBC units are non-irradiated, leukoreduced before storage, and stored 
in SAGM for a maximum of 35 days. Patients who underwent stem cell transplantations received 
irradiated RBCs with a maximum storage time of 14 days after irradiation. Before transfusion, 
screening for warm reacting clinically significant antibodies is routinely performed and retesting 
using a newly drawn serum for transfusion is mandatory every 72 hours.
Responders and nonresponders
Patients who developed anti-K during follow-up were defined as responders. When anti-K was 
detected within 2 weeks after transfusion of a K+ unit, a memory (booster) response could not 
be excluded and these patients were excluded. Nonresponders were defined as patients who 
received at least one K+ transfusion without anti-K seroconversion after a follow-up period of at 
least 30 days.
Statistical analyses of the storage time of K+ RBCs
The storage time of K+ RBC units was analyzed as a continuous (mean, maximum, minimum), a 
categorical (2-14 days as the reference category, 15-21 days, and longer than 21 days), and as a 
dichotomous variable (using different cutoff points: 14, 18, and 21 days defining “only older” vs. 
“only younger” blood).
Relative risks (RRs) and adjusted relative risks (aRRs) were estimated using Poisson regression 
models with robust standard errors and expressed with 95% confidence intervals (CIs).12 To 
adjust for confounding, the multivariable analysis was corrected for number of transfusions. 
Because of the nonlinearity of the relation between the number of transfusions and the outcome, 
the multivariable model was also adjusted for the number of transfusion as a quadratic term. A 
sensitivity analysis was performed including only patients who received only 1 K+ unit or 2 K+ 
units with the same storage time on the same day. This way, only patients of whom the storage 
time of the immunizing unit was certain were analyzed.
Statistical analyses of the storage time of K− RBC
Exploratory analyses of the storage time of concomitantly transfused K− units were performed for 
different periods surrounding the K+ transfusion event:
• Day 0 (transfusion date of the first K+ unit(s)).
• 30, 15, 7, and 1 day(s) before and after the K+ transfusion event.
To validly analyze the association between the storage time of K− RBCs and anti-K formation, 
within a given period of time surrounding a K+ transfusion, K− transfusions could be considered 
only once, that is, in one event. Therefore, only patients who received all K+ RBCs in a single 
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transfusion event were included in this analysis. The association between storage time of K− 
RBCs and anti-K formation was analyzed in the same way as the K+ units (i.e., mean, minimum, 
maximum storage time, as a categorical variable, and “only old” vs. “only young”).
Results
Of the 297 patients included in this study, 124 patients received 1 K+ unit, 75 patients received 
2, and 98 patients received 3 or more K+ units. A total of 23 patients (7.7%) seroconverted with 
anti-K during follow-up (responders) and 274 did not. In 18 patients (78%) anti-K was formed 
after one K-incompatible transfusion event and of these patients 15 had received only 1 K+ unit. 
The remaining five responders received 2 to 3 K+ RBC units during two transfusion events before 
seroconversion.
Baseline and transfusion characteristics for responders and nonresponders are presented in 
Table 1. Responders were older, were more often female, suffered less often from hematological 
malignancies, and received fewer solid organ transplantations. The storage time of the RBCs 
transfused, both K− and K+, ranged from 2 to 34 days, as displayed in Fig. 1.
* Data are reported as number (%) or median (interquartile range).
Nonresponders had a longer follow-up time, received more (both K+ and K−) RBC transfusions 
and more antibody tests were performed in these patients. Non-K antibodies were formed by 35 
(11.8%) patients: in two patients before anti-K, in seven patients together with or after anti-K, and 
in 26 patients without anti-K.
In anti-K responders, the mean, minimum, and maximum storage times of the K+ RBCs had a 
median of 15 days (interquartile range ranging from 12 to 20 days). In nonresponders the mean, 
maximum, and minimum storage times of K+ RBCs had a wider range. Results are displayed in 
Table 2.
Characteristics of 297 patients with     
  













Table 1. Characteristics of 297 patients with and without anti-K*
          Responders
N=23 
                         Nonresponders
N=274
Female, N (%)                                                                        8 (34.8) 83 (30.3)
Age 62 (54-71)   58 (47-63)
Diagnosis, 
 - Hematological malignancy  5 (21.7)                            200 (73.0)
 - Solid organ malignancies   7 (30.4) 9 (3.3)
 - Transplantation                   1 (4.3)              35 (12.8)
 - Other  10 (43.5) 30 (10.9)
 - nonsurgical 4 (40.0) 15 (50.0)
 - Surgical 5 (50.0) 5 (16.7) 
 - Renal failure 1 (10.0) 10 (33.3) 
Patients with non-K anti-bodies 9 (39.1) 26 (9.5) 
Anti-K formation is not associated with the storage time of transfused red blood cells
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Total number of RBC units transfused 8 (5-14) 16 (6-24) 
Number of K+ RBC units transfused 1 (1-2) 2 (1-3)
Storage time of K+ units (days)
- Mean 15 (13-20) 16 (12-20)
- Minimum 15 (12-20) 13 (10-18)
- Maximum 15 (14-21) 18 (14-23)
Storage time of K- units (days)
- Mean 15 (13-19) 15 (13-18)
- Minimum 11 (7-14) 9 (6-14)
- Maximum 19 (14-28) 22 (17-29)
Follow-up time (months)† 13 (4-34) 22 (7-48)
Number of antibody test during follow-up 2 (1-4) 15 (10-23)
 
* Data reported in median (interquartile range)




Figure 1: Storage time of all RBCs transfused (K+ and K− RBCs).
 
Figure 1. Storage time of all RBCs transfused (K+ and K− RBCs)
* Data reported in edian (interquartile range)
† Follow-up time: from the first K+ transfusion until the positive antibody test for anti-K or the last antibody test 
performed
Anti-K formation was not associated with the mean, the maximum, or the minimum storage times 
of the K+ units (aRR mean storage time 1.02, 95% CI 0.96-1.08; aRR maximum storage time 1.01, 
95% CI 0.96-1.07; and aRR minimum storage time 1.03, 95% CI 0.97-1.09). Also, no association was 
found when the storage time of K+ RBCs was analyzed as a categorical variable (with 2-14 days as 
reference category, 15-21 days, aRR 1.10, 95% CI 0.43-2.81; ≥22 days, aRR 1.18, 95% CI 0.36-3.43).
Similarly, no association between anti-K formation and receiving only-old or only-young RBCs 
was found (aRR cutoff 14 days 1.00, 95% CI 0.43-2.35; aRR cutoff 18 days 1.02, 95% CI 2.55; aRR 
cutoff 21 days 1.21, 95% CI 0.07-5.88; Tables 3 and 4).
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Table 3. Association between the storage time of K+ RBCs and the formation of 




















Maximum 0.98 0.93-1.03 0.472 1.01 0.96-1.07 0.629
Minimum 1.06 1.00-1.12 0.037 1.03 0.97-1.09 0.399
Mean storage time K+ RBC in categories (days)
2-14 1 Ref. Ref. 1 Ref. Ref. 
15-21 1.08 0.42-2.76 0.870 1.10 0.43-2.81 0.838
> 22 1.30 0.40-3.75 0.627 1.18 0.36-3.43 0.752
 





Table 4. Association between only “older” and “younger” K+ RBCs and anti-K formation
    
Crude
   
Adjusted*
 
Cut off point (days) number RR 95% CI p-value RR 95% CI p-value
2-14 vs. > 15 217 (20 responders) 1.09 0.45-2.80 0.834 1.00 0.43-2.35 0.993 
2-18 vs. > 19 223 (20 responders) 1.14 0.46-2.83 0.780 1.02 0.36-2.55 0.964
2-21 vs. > 22 268 (23 responders) 1.99 0.32-12.42 0.464 1.21 0.07-5.88 0.849
 
* Adjusted for number of transfusions and for the numbers of transfusions square
 
* Adjusted for number of transfusions and for the numbers of transfusions square
* Adjusted for number of transfusions and for the numbers of transfusions square
The sensitivity analysis was performed in the subgroup of patients in which the immunizing K+ 
unit and its storage time was identified with certainty. The sensitivity analysis revealed similar 
results. 
 
Sensitivity analysis I: Association between the storage time of K+ RBC and the formation of anti-K
in patients who received 1 K+ RBC unit (N = 130, 16 responders)
 







Mean 1.05 0.98-1.11 0.156 
Mean storage time K-positive RBC in categories:
 RR 95% CI P-value
2-14 days 1 - - 
15-21 days 1.54 0.49-5.19 0.437
> 22 days 1.95 0.48-7.36 0.285 
 
Anti-K formation is not associated with the storage time of transfused red blood cells
Sensitivity Analysis II: Association between only ‘older’ and ‘younger’ K+ RBC and anti-K formation 
in patients who received 1 K-positive RBC unit (N = 130, 16 responders) 
 









  2-14 vs > 15 130 1.67 0.61-4.52 0.317 
                       2-18 vs > 19 130 1.40 0.54-3.58 0.483 
                       2-21 vs > 22 130 1.40 0.22-8.77 0.734 
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Table 6. Association between only “older” and “younger” K- RBCs and anti-K formation in patients
with one K+ transfusion episode (K- RBCs transfused during the K+ transfusion episode)
    
Crude
   
Adjusted*
 
Cut off point (days) number RR 95% CI p-value RR 95% CI p-value
2-14 vs. > 15 71 (10 responders) 1.16 0.36-3.76 0.802 1.11 0.35-3.50 0.859 
2-18 vs. > 19 88 (12 responders) 1.30 0.39-4.30 0.672 1.30 0.40-4.27 0.664
2-21 vs. > 22 98 (13 responders) 0.82 0.12-5.63 0.824 0.84 0.11-6.36 0.866
 




Table 5. Association between the storage time of K- RBCs and the formation of 
Table 5. anti-K in patients with one K+ transfusion episode





Storage time RR 95% CI p-value RR 95% CI p-value
K- RBCs       
Mean 1.04 0.96-1.12 0.632 1.04 0.96-1.12 0.352
Maximum 1.03 0.96-1.10 0.467 1.03 0.96-1.10 0.427
Minimum 1.03 0.96-1.10 0.425 1.03 0.97-1.11 0.391
Mean storage time K- RBC in categories (days)
 
2-14 1 Ref. Ref. 1 Ref. Ref. 
15-21 1.43 0.53-4.00 0.446 1.42 0.53-3.98 0.448
> 22 1.01 0.15-4.17 0.991 1.03 0.15-4.27 0.971
 
* Adjusted for number of transfusions and for the numbers of transfusions square
 
 
Storage time of concomitantly transfused K− units and anti-K formation
A total of 160 patients (18 responders and 142 nonresponders) had only one K+ transfusion event 
and were included in the exploratory analyses of the storage time of the concomitantly transfused 
K− units. The mean, maximum, and minimum storage times of the K− units that were transfused 
on the same day as the K+ units were not associated with anti-K formation (mean storage time 
aRR 1.02, 95% CI 0.95-1.10; maximum storage time aRR, 1.02, 95% CI 0.95-1.09; minimum storage 
time aRR 1.01, 95% CI 0.93-1.09). No association was observed when the storage time was 
analyzed categorically nor when analyzing only “older” versus only “younger” K− units (Tables 5 
and 6). When these analyses were performed for K− units transfused in the periods 1, 7, 15, and 30 
day(s) before and after the transfusion event, combined or separately no associations were found.
* Adjusted for number of transfusions and for the numbers of transfusions square
* Adjusted for number of transfusions and for the numbers of transfusions square
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Discussion
In this study no association between the storage time of K+ or concomitantly transfused K− RBCs 
and the formation of anti-K was observed. Only two clinical studies analyzed the association 
between the storage time of RBCs and antibody formation. Zalpuri and coworkers found 
no association in a matched case-referent study between RBCs with a storage time of 1 to 4 
weeks and any alloantibody formation.10 However, this study included weak as well as strong 
immunogenic RBC antigens and could not conclude on the influence of storage time of RBCs 
with specific antigens and cognate antibody formation. Yazer and Triulzi performed a matched
case-control study in D− patients receiving multiple D+ transfusions mainly in emergency 
situations.9 In this study the D+ transfusions had different storage times and only the mean and 
median storage interval of D+ units in responders and nonresponders could be compared and 
no differences were found. In addition, both studies defined nonresponsiveness already after a 
follow-up of 13 or 20 days after transfusion, which may be too short to detect antibody formation 
in a proportion of patients.
The current study allowed us to compare the storage times of the actual immunizing K+ RBC 
in responders and in nonresponders with a follow-up time of at least 30 days. Furthermore 
we analyzed the storage time of the concomitantly transfused K− units because one could 
hypothesize that these units could dampen or enhance anti-K formation.
The assumption that a longer storage time of transfused RBC enhances immunization is based 
on the concept that concomitant danger signals are required for an immune response.13 Such 
signals may be provided by pro-inflammatory cytokines accumulating during RBC storage.8,14 
In a mouse model, Hendrickson and colleagues demonstrated that a stronger alloantibody 
response after transfusion with “old” murine RBC (which had been stored for more than 14 days) 
was associated with increased levels of pro-inflammatory cytokines.8 This response was blunted 
when mice were concomitantly transfused with antigen-expressing “young” RBCs that contained 
fewer pro-inflammatory cytokines.8,15 Our study could not reproduce these associations, which 
may be explained by the difference in the murine and human RBC lifespan.16 The natural lifespan 
of mouse RBCs is estimated to be 38 to 55 days.8 A storage time of 14 days (which was the cutoff 
point in the mouse model) approximates human RBCs with a storage time over 35 days, which is 
the maximum allowed storage time in the Netherlands and rarely used in daily practice.15,17 The 
K+ as well as the concomitantly transfused K− RBCs in our study may thus lack the metabolic 
changes that enhanced anti-K formation in the mouse. Also we did not observe a dampening of 
the antibody response associated with more fresh K− units during the same transfusion event as 
the K+ units.
To appreciate the results of this study, some issues need to be discussed. The majority of 
responders developed anti-K after a single K-incompatible transfusion; this indicates that one RBC 
transfusion is sufficient to induce a prompt and strong immunoglobulin G response. Furthermore, 
the detection of RBC antibodies is dependent on the follow-up period and frequency of antibody 
testing. Differences in these characteristics in populations under study may influence the 
outcome. In the nonresponders the follow-up time after each K+ unit was at least 30 days and 
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total follow-up time and number of antibody test were sufficient to detect anti-K if it had been 
present. In this study, nonresponders had a longer follow-up time and received more RBCs. This 
explains the differences in ranges found between responders and nonresponders regarding the 
maximum and minimum storage time.18
There are a number of limitations of our study. Most important, with the differences in 
immunocompetence between responders and nonresponders one would prefer to stratify 
analyses according to diagnosis. Patients with a hematological malignancy and transplant 
patients using immunosuppressant drugs are low responders, with only 2.6% anti-K responders 
in our cohort, while surgical patients or patients with a solid tumor, previously identified as high 
responders, produced anti-K in 44%.19,20 Unfortunately, our small sample size prohibited us to 
stratify according to diagnosis. Another limitation is that no standardized follow-up measurements 
were in place. Although patients with anti-K detected within 14 days after transfusion of the first 
K+ RBCs were excluded, not all seroconverted patients had been tested within 14 days after the 
first K+ transfusion. In theory, some of these patients may have had a booster reaction after prior 
pregnancies or unknown transfusions in other hospitals, instead of a primary anti-K response. And 
last, the storage times of the RBC units fell within a small interval and numbers of very fresh and 
end-of-shelf life units were insufficient to study the extremes.
In conclusion, in this study no association between anti-K formation and the storage time of K+ 
or concomitantly transfused K− RBCs was observed. The results are based on current transfusion 
practice with regard to storage time and make an association between storage time and anti-K 
alloimmunization less likely. Which factors are most important in the formation of alloantibodies 
in humans and if these factors contribute equally for the different RBC antigen specificities 
remains a subject for further research.
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Does a platelet transfusion 
independently affect bleeding and 
adverse outcomes in cardiac surgery?
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Conflicting results have been reported concerning the effect of platelet transfusion on several 
outcomes. The aim of this study was to assess the independent effect of a single early intraoperative 
platelet transfusion on bleeding and adverse outcomes in cardiac surgery patients.
Methods
For this observational study 23,860 cardiac surgery patients were analyzed. Patients who received 
one early (shortly after cardiopulmonary bypass while still in the operating room) platelet 
transfusion, and no other transfusions, were defined as the intervention group. By matching 
the intervention group 1:3 to patients who received no early transfusion with most comparable 
propensity scores, the reference group was identified. 
Results
The intervention group comprised 169 patients and the reference group 507. No difference 
between the groups was observed concerning reinterventions, thromboembolic complications, 
infections, organ failure and mortality. However, patients in the intervention group experienced 
less blood loss and required vasoactive medication 139/169 (82%) versus 370/507 (74%), (odds 
ratio 1.65; 95%-confidence interval1.05-2.58); prolonged mechanical ventilation 92/169 (54%) 
versus 226/507 (45%) (1.47;1.03-2.11); prolonged intensive care 95/169 (56%) versus 240/507 
(46%) (1.49;1.04-2.12); red cells 75/169 (44%) vs 145/507 (34%) (1.55;1.08-2.23), plasma 29/169 
(17%) vs 23/507 (7.3%) (2.63;1.50-4.63) and platelets 72/169 (43%) vs 25/507 (4.3%) (16.4;9.3-28.9) 
more often compared to the reference group.
Conclusions
In this retrospective analysis, cardiac surgery patients receiving platelet transfusion in the operating 
room experienced less blood loss and more often required vasoactive medication; prolonged 
ventilation; prolonged intensive care and blood products postoperatively. However, early platelet 
transfusion was not associated with reinterventions, thromboembolic complications, infections, 
organ failure, or mortality.
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Introduction
Patients undergoing cardiac surgery are at increased risk for excessive bleeding. Excessive 
bleeding may lead to surgical re-exploration. Both excessive blood loss and re-exploration are 
associated with increased postoperative mortality and morbidity.1–3 Thus efficient prevention and 
treatment of the cause of bleeding is an important issue in cardiac surgery. As expected, part 
of the postoperative bleedings is due to surgically induced injury, but a significant proportion 
of the observed bleedings can be explained by acquired hemostatic defects.4,5 Impaired 
platelet function, mainly due to cardiopulmonary bypass (CPB) and anti-platelet drug therapy, 
is considered one of the most important hemostatic factors leading to postoperative bleeding.4–8 
Platelet transfusions are thus commonly administered to treat bleeding.9
The platelet-transfusion rates vary greatly in cardiac surgery, both nationally and internationally, in 
spite of existing guidelines.10,11 This wide variety in platelet transfusion use among cardiac surgery 
centres illustrates the lack of consensus on the indication for a platelet transfusion in certain 
clinical situations. Presumed platelet dysfunction in patients using platelet-inhibiting drugs is not 
always confirmed by a measurement before platelets are transfused. Furthermore, just as in other 
clinical areas, there is a lack of clinical evidence establishing the effectiveness of administering 
platelets in cardiac surgery.12–14
In addition, conflicting results have been reported concerning the effect of platelet transfusions 
on serious adverse events, like stroke, infections, vasoplegia and death in cardiac surgery.15–22 The 
recently published results of a multicenter randomized controlled trial (Platelet Transfusion in 
Cerebral Haemorrhage trial) comparing standard care to standard care with platelet transfusion 
in patients using antiplatelet therapy before intracerebral hemorrhage, showed that platelet 
transfusions seemed inferior to standard care.23
Our hypothesis was that a single early platelet transfusion, in the absence of concomitant 
erythrocyte or plasma transfusion, is associated with less bleeding complications and is associated 
with more adverse events, in patients undergoing cardiac surgery.
Patients and methods
Data collection
The analyses were performed using data from the Amphia Cardiac Surgery Registry consisting of 
23,860 patients who underwent cardiac surgery at the Amphia Hospital (Breda, The Netherlands) 
between 1997 and 2013.
Details of this database have been described previously.24 In this ongoing cohort study detailed 
baseline and perioperative data of all consecutive patients undergoing cardiac surgery in the 
Amphia Hospital (Breda, The Netherlands) were collected. Data collection for the current 
analysis took place between January 1st 1997 and January 1th 2013 and was compliant with the 
definitions of the Dutch National Cardiac Surgery Registry and the Dutch National Intensive Care 
Registry (instituted in 1996).25 All patient-care decisions were taken by the attending physician in 
accordance with transfusion and coagulation hospital guideline based protocols. Members of 
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our departmental review committee critically reviewed the analytical plan. The aim of the study, 
the inclusion and exclusion criteria, propensity score matching as the method to correct for 
confounding by indication, the postoperative endpoints, and logistic regression as the method 
to analyse the endpoints were determined before examination of the data. There was no a 
priori statistical power analysis calculation used to guide sample size. Sample size and analyses 
were based on the available data. The ratio and caliper of the propensity score matching were 
determined during examination of the data. An acknowledged Dutch medical ethical committee 
approved this study protocol and waived individual patient consent.
Patient sample
It was decided in advance to select only patients who received one early platelet transfusion, 
defined as one platelet transfusion after end of CPB while still in the operating room. Patients 
transfused with more than one unit of platelets were excluded presuming that these patients 
would not be comparable to patients who were not transfused with platelets. Also patients who 
received other blood products in the operating room were excluded aiming at studying the 
independent effect of an early platelet transfusion without the potential influence of erythrocyte 
or fresh frozen plasma (FFP) transfusions.
The platelet units transfused in this study consisted of 5 pooled buffy coats and contained 
approximately 300 x 109 platelets suspended in plasma with or without platelet additive solution. 
Since 2001, all platelet units were prestorage leukocyte reduced in The Netherlands and before 
2001 platelet units were leukocyte reduced when indicated in the Amphia hospital (Breda, 
The Netherlands). The decision to transfuse platelets was made according to a cardiac surgery 
coagulation algorithm, with up scaling treatment modalities in which platelet transfusion is used 
as a last resort after considering other pharmacological strategies. Some degree of freedom was 
left to the discretion of the physicians, but platelet count lower than 50 x 109/L was an indication 
for platelet transfusion in any case. When platelet count was lower than 100 x 109/L and bleeding 
was present, this was also indication for transfusion of platelets. No specific platelet function test 
was available, but in recent years rotational thromboelastometry was included in the algorithm.
Patients who received an early platelet transfusion may differ in various ways from patients 
who received no early transfusion because there was a reason to administer the platelet unit 
(confounding by indication). To correct for this confounding we estimated a propensity score 
for these patients, representing the probability that the patient received platelets conditional 
on relevant covariates prior to the decision to transfuse platelets. The patients who received one 
early platelet transfusion and no other blood products, and were suitable for propensity score 
matching were defined as the intervention group. The intervention group was then matched 
to the reference group, consisting of patients who received no early transfusion and had the 
closest propensity scores. We hereby aimed at selecting an intervention and reference group 
with comparable baseline characteristics. We excluded patients in whom an intraoperative 
circulatory arrest was part of the surgical procedure because of their exceptional hemodynamic 
and hemostatic state. Furthermore, Jehovah’s witnesses were excluded as they may be treated 
with different surgical and anesthesiological strategies.
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Postoperative outcomes
As a result of numerous previous articles reporting contradictory results about the effect of platelet 
transfusion in cardiac surgery patients, the aim of our study was to obtain an overall picture of 
all potential consequences for a clinician who is considering an early platelet transfusion for a 
cardiac surgery patient. So before initiation of the analysis of this study we defined the outcomes 
we were interested in (based on previous literature and clinical knowledge). Our objective was to 
study not only the intended effects of an early platelet transfusion (preventing / treating bleeding 
complications), but also the possible adverse events associated with a platelet transfusion. We 
aimed at analysing all relevant factors, so both the potential beneficial effects and the potential 
undesired effects. We planned to study the following postoperative outcomes: amount of 
blood loss within 12h, early reexploration for bleeding and/or tamponade, late intervention 
for tamponade, stroke, myocardial infarction (MI), infections, systemic inflammatory response 
syndrome, shock, acute kidney injury, multi organ failure, in-hospital mortality, and a composite 
endpoint (consisting of myocardial infarction, stroke, acute kidney injury and in-hospital 
mortality). Definitions of postoperative myocardial infarction, acute kidney failure and stroke 
were described earlier.21 Infection was categorized as pneumonia, mediastinitis, sepsis and other 
infections with the diagnoses requiring organisms isolated from culture(s) in combination with 
elevated temperature and white blood cell counts. Systemic inflammatory response syndrome 
was diagnosed if two or more of the following criteria were present: temperature greater than 
38 or less than 36 degree Celsius; tachypnea (greater than 20 per minute) or hypocapnea (pCO2 
less than 32 mmHg); tachycardia (greater than 90 beats/min); or need of mechanical ventilation 
and leukocyte count greater than 12 or less than 4 x 109/L. Multiorgan failure was defined as 
simultaneous or sequential dysfunction or failure of two or more organ systems. Shock was defined 
as a syndrome in which the effective capillary and tissue perfusion declined to a level detrimental 
to cellular metabolism. Also we compared duration of postoperative mechanical ventilation and 
intensive care unit (ICU) stay (both in hours), requirement of postoperative inotropic or vasoactive 
drugs and erythrocyte, FFP and platelet transfusions in the ICU. Amount of blood loss, duration 
of mechanical ventilation, and ICU stay were analyzed as being high or low, with the median as 
the cutoff point.
Statistical analysis
The continuous baseline variables were summarized by medians and interquartile ranges and 
the categorical variables were summarized by frequencies and percentages. The propensity score 
was generated with logistic regression and the variables where the propensity score was based 
on were chosen based on previous knowledge of the subject, as suggested in earlier papers.26–28 
The following preoperative variables were included in the propensity score: age, gender, year of 
surgical procedure (per calendar year), previous cardiac surgery, history of MI, number of affected 
coronary arteries, left ventricular hypertrophy, acetylsalicylic  acid or clopidogrel use (continued 
up to surgery, stopped preoperatively or never used), known vascular disease, chronic obstructive 
pulmonary disease, diabetes, atrial fibrillation, angina pectoris, active endocarditis, hemoglobin 
level, international normalized ratio, acute or chronic renal failure, left ventricular ejection 
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fraction, immunosuppressant drug use, type of surgery, non-elective surgery, cardiopulmonary 
resuscitation within 24 hour before surgery, respiratory insufficiency, off-pump surgery, CPB 
duration and European System for Cardiac Operative Risk Evaluation (EuroSCORE). It was not in all 
years part of standard care to determine fibrinogen level and platelet function before surgery and 
/ or transfusion, so these measures were not available for analysis. Missing variables were imputed 
using single imputation strategies. For the propensity score matching we used the “psmatch2” 
function in Stata Statistical Software (Release 14; StataCorp LP, USA), nearest neighbour 1:3 
matching with replacement. Only controls with a propensity score within 0.01 distance (caliper) 
of the propensity score of the case were selected.29 To assess the balance in measured baseline 
characteristics after propensity score matching between treated and untreated patients, the 
standardized mean differences were determined. The matching procedure was optimized based 
on observed balance in baseline variables before examination of the outcome results. Comparisons 
of outcomes were made between the intervention and reference group with regard to odds 
ratios with 95% confidence intervals derived from multiple univariate logistic regression analyses. 
Given the fact that 1:3 matching with replacement was applied, the clustered pattern of the data 
was taken into account in the estimation procedure by using a robust (sandwich) estimator in 
the logistic regressions, specifying the patient identifying number. Additionally, we performed 
two sensitivity analyses. Firstly, we corrected the logistic models for baseline characteristics 
that remained unbalanced after the matching procedure. Secondly, we corrected the logistic 
regressions for a baseline characteristic with standardized difference below 10%, because of its 
high clinical relevance. No adjustments were made for testing multiple outcomes.
Results
Patient characteristics
The database comprised 23,860 patients in total, of whom 17,918 remained after application of 
the exclusion criteria (shown in figure 1).
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Figure 1: Flow chart exclusions. FFP = fresh frozen plasma; OR = operating room; PSM = propensity score matching. 
 Figure 1. Flow chart exclusions. FFP = fresh frozen plasma; OR = operating room; PSM = propensity score matching
Several of the relevant baseline characteristics of the 171 patients who received an early platelet 
transfusion were evidently different from the ones of the 17,747 patients who received no early 
transfusions (shown on the left side of table 1). By propensity score matching, the patients were 
selected from the 17,747 patients who received no early transfusion and were most comparable 
with the patients who received an early platelet transfusion. Of the 171 patients who received one 
early platelet transfusion, 169 patients had propensity scores overlapping with the propensity 
scores of the patients who received no early transfusions (i.e. had the same “baseline risk” of 
receiving a platelet transfusion). 
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Table 1. Patient Characteristics Before and After Propensity Score Matching
 




















Female sex* 33(19.3) 4.107(23.1) 9.4 32(18.9) 97(19.1) 0.5 
Age (yr)* 67(61-74) 66(59-73) 0.5 67(60-73) 67(58-73) 4.3 
Weight (kg) 81(75-90) 80(72-90) 10.2 81(75-90) 80(73-90) 9.9 
Year of surgery* 2003(1998-2008) 2004(2001-2009) 26.5 2003(1998-2008) 2003(1999-2007) 2.5 
Previous cardiac surgery* 21(12.3) 1290(7.3) 16.9 21(12.4) 56(13.2) 2.7 
History of MI* 83(48.5) 6.441(36.3) 24.9 81(47.9) 253(49.9) 4.0 
Affected coronary arteries* 3(1-3) 3(1-3) 7.9 3(1-3) 3(1-3) 4.3 
LV hypertrophy* 50(29.2) 3623(20.4) 20.5 50(29.6) 166(32.7) 7.3 
LMCA occluded > 50% 30(17.5) 2661(15.0) 6.9 29(17.2) 95(18.7) 4.3 
Acetylsalicylic acid use* 
- Continued up to surgery 21(12.3) 1133(6.4) 20,3 20(11.8) 60(11.8) 0.0 
- Stopped before surgery 81(47.4) 9181(51.7) 8.7 81(47.9) 253(49.9) 3.9 
- Never 69(40.4) 7433(41.9) 3.1 68(40.2) 194(38.3) 4.0 
Clopidogrel use* 
- Continued up to surgery 20(11.7) 362(2.0) 38.8 19(11.2) 59(11.6) 1.6 
- Stopped before surgery 32(18.7) 1974(11.1) 21.4 31(18.3) 101(19.9) 4.4 
- Never 119(69.6) 15411(86.8) 42.6 119(70.4) 347(68.4) 4.9 
Hypertension 85(49.7) 9433(53.2) 7.0 84(49.7) 251(49.5) 0.4 
Hypercholesteremia 105(61.4) 11583(65.3) 8.0 105(62.1) 325(64.1) 4.1 
Smoking 29(17.0) 3560(20.1) 8.0 28(16.6) 98(19.3) 7.1 
Vascular disease* 26(15.2) 2558(14.4) 2.2 25(14.8) 76(15.0) 0.6 
COPD* 21(12.3) 2485(14.0) 5.1 20(11.8) 53(10.5) 4.1 
Diabetes mellitus* 
Diabetes mellitus I 3(1.8) 545(3.1) 8.6 3(1.8) 7(1.4) 2.6 
Diabetes mellitus II 23(13.5) 2617(14.7) 3.7 23(13.6) 70(13.8) 0.6 
Atrial fibrillation* 20(11.7) 2404(1313.5) 5.6 20(11.8) 53(10.5) 3.6 
Endocarditis* 3(1.8) 84(0.5) 12.2 3(1.8) 9(1.8) 0.0
Pre-operative hemoglobin (g/dL)* 14.0(13.2-15.0) 14.2(13.2-15.0) 9.0 14.0(13.2-15.0) 14.2(13.0-15.0) 0.7 
APTT, s 34(28-40) 32(28-38) 23.5 34(28-40) 33(28-40) 4.0 
INR*
• < 1.5 122(71.3) 13620(76.7) 12.3 122(72.2) 356(70.2) 4.5
• 1.5 - 2.5 38(22.2) 3472(19.6) 6.5 37(21.9) 120(23.7) 4.4
• > 2.5 11(6.4) 655(3.7) 12.5 10(5.9) 31(6.1) 0.9
Creatinine, µmol/l 88(76-101) 86(75-99) 7.2 88(76-101) 88(77-103) 1.8 
Chronic renal failure* 2(1.2) 218(1.2) 0.5 2(1.2) 2(0.4) 7.2 
Acute renal failure* 4(2.3) 130(0.7) 13.1 4(2.4) 12(2.4) 0.0 
Left ventricular ejection fraction* 
• >50% 110(64.3) 13386(75.4) 24.3 108(63.9) 344(67.9) 8.6
• 25-50% 42(24.6) 2813(15.9) 21.7 42(24.9) 107(21.1) 9.4
• < 25% 19(11.1) 1548(8.7) 8.0 19(11.2) 56(11.1) 0.7
Immunosuppressive drugs* 8(4.7) 604(3.4) 6.5 7(4.1) 25(4.9) 4.0 
Tricuspid valve pathology 6(3.5) 476(2.7) 4.8 6(3.6) 16(3.2) 2.3 
Mitral valve pathology 33(19.3) 2449(13.8) 14.8 32(18.9) 88(17.4) 4.3 
Aortic valve pathology 42(24.6) 3885(21.9) 6.3 42(24.9) 115(22.7) 5.1 
Type of surgery* 
• Isolated CABG 115(67.3) 12532(70.6) 7.3 114(67.5) 351(69.2) 3.8
• Other than isolated CABG 56(32.7) 5215(29.4) 7.3 55(32.5 156(30.8) 3.8
EuroSCORE I* 6(3-9) 4(2-7) 50.5 6(3-9) 6(3-9) 6.7 
NYHA class IV* 35(20.5) 2871(16.2) 11.1 34(20.1) 88(17.4) 7.1 
Nonelective surgery* 42(24.6) 1089(6.1) 52.8 41(24.3) 114(22.5) 5.1 
CPR in 24 h before surgery* 6(3.5) 128(0.7) 19.4 6(3.6) 16(3.2) 2.7 
 
Intra-operative variables
Surgical procedure time, min 251(208-310) 233(196-275) 30.0 251(208-307) 255(210-300) 4.4 
Aortic occlusion time, min 69(47-95) 61(44-80) 37.0 69(48-95) 68(53-90) 0.2 
CPB use* 163(95.3) 15653(88.2) 26.1 161(95.3) 488(96.3) 3.6 
CPB time, min* 106(78-149) 91(69-116) 48.8 106(78-148) 104(83-136) 3.5 
Cellsaver blood given, yes/no 64(37.4) 6203(35.0) 5.1 64(37.9) 166(32.7) 10.7 
Nadir hemoglobin (g/dL) 8.6(7.7-9.5) 8.7(7.9-9.7) 11.1 8.6(7.8-9.5) 8.7(7.6-9.5) 10.5
 
Continuous variables are reported as median with interquartile range, and categorical variables are reported as counts with percentages. 
Standardized differences are reported in % for assessing balance. 
*Marks variables that were used to calculate the propensity score. 
APTT = activated partial thromboplastin time; CABG = coronary artery bypass graft; COPD = chronic obstructive pulmonary disease; CPB = 
cardiopulmonary bypass; CPR = cardiopulmonary resuscitation; INR = international normalized ratio; LMCA = left main coronary artery; LV = left 
ventricle; MI = myocardial infarction; NYHA = New York Heart Association; SMD = standardized mean difference. 
Continuous variables are reported as median with interquartile range, and categorical variables are reported as 
counts with per entages. Stand rdized differences re re orted in % for asse sing bala ce.
*Marks variables that were used to calculate the propensity score.
APTT = activated partial thromboplastin time; CABG = coronary artery bypass graft; COPD = chronic obstructive 
pulmonary disease; CPB = cardiopulmonary bypass; CPR = cardiopulmonary resuscitation; INR = international 
normalized ratio; LMCA = left main coronary artery; LV = left ventricle; MI = myocardial infarction; NYHA = New 
York Heart Association; SMD = standardized mean difference.
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Blood loss > 500ml first 12 h 79(46.7) 290(57.2) 0.66(0.46-0.94) 0.021 
Early reexploration for bleeding and/or tamponade 4(2.4) 23(4.5) 0.51(0.17-1.52) 0.227
Late intervention for tamponade 4(2.4) 6(1.2) 2.02(0.52-7.89) 0.309
 
The absolute numbers and percentages of patients in the intervention and the reference group are given, the regression 
derived odds ratios with 95% CI and exact P values. 
 
So these 169 patients were suitable for propensity score matching and thereby formed the 
intervention group. The reference group, which was formed after 1:3 propensity score matching, 
consisted of 507 patients (who had not received any blood product in the operating room). 
Considering the fact that matching with replacement was used control patients could be used 
multiple times: 444 controls were used once, 24 controls were used twice and 5 were used three 
times, summing up to 473 unique controls out of 507 controls in total.
The majority of patients were men (81%), the median age was 67 year, and about half the patients 
(49%) had a history of MI. Most patients underwent isolated coronary artery bypass graft (69%), 
and almost one quarter (23%) of all procedures was a nonelective procedure. As expected, the 
balance of multiple clinically important variables improved after propensity score matching. 
Among others the balance of gender, year of surgery, history of MI, clopidogrel use, type of surgery, 
EuroSCORE, nonelective surgery, cardiopulmonary resuscitation within 24 h before surgery and 
CPB time improved remarkably (shown on the right side of table 1). Standardized differences for 
the baseline characteristics are reported for the unmatched and matched groups. Two of the 
measured covariates, “cellsaver blood returned or not” and “nadir intraoperative hemoglobin”, had 
standardized differences that slightly exceeded 10%, indicative of imbalance in these covariates 
between matched-treated and untreated patients. The second sensitivity analysis was not only 
corrected for variables with standardized differences above 10%, but also for a variable with better 
balance, but with high clinical relevance, namely the EuroSCORE.
Early platelet transfusion and outcomes
Patients in the intervention group less often experienced blood loss higher than 500mL than 
patients in the reference group (odds ratio 0.66, 95% CI, 0.46 to 0.94). However, the number 
of early reexplorations for bleeding and/or tamponade and number of late interventions for 
tamponade of patients in the intervention group did not significantly differ from that of patients 
in the reference group (table 2).
The absolute numbers and percentages of patients in the intervention and the reference group are given, the 
regression derived odds ratios with 95% CI and exact P values.
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Stroke* 5(3.0) 16(3.2) 0.94(0.32-2.71) 0.902 
Myocardial infarction* 25(14.8) 57(11.2) 1.37(0.82-2.28) 0.226
Patients with postoperative infection 35(20.7) 88(17.4) 1.24(0.79-1.94) 0.340
- Mediastinitits 2(1.2) 1(0.2) 6.06(0.54-67.4) 0.143
- Superficial wound infection 1(0.6) 2(0.4) 1.50(0.14-16.7) 0.740
- Pneumonia 4(2.4) 13(2.6) 0.92(0.30-2.87) 0.887
- Sepsis 11(6.5) 23(4.5) 1.47(0.70-3.08) 0.313
- Other infections 27(16.0) 62(12.2) 1.36(0.82-2.27) 0.230
SIRS 13(7.7) 25(4.9) 1.61(0.79-3.25) 0.187
Shock 28(16.6) 67(13.2) 1.30(0.79-2.14) 0.296
CVVH de novo* 9(5.3) 19(3.7) 1.44(0.63-3.30) 0.383
Multiorgan failure 7(4.1) 16(3.2) 1.33(0.53-3.34) 0.549
In-hospital mortality* 7(4.1) 13(2.6) 1.64(0.64-4.19) 0.300
Composite Endpoint 34(20.1) 89(17.6) 1.18(0.76-1.85) 0.462
Ventilation > 11h 92(54.4) 227(44.8) 1.47(1.03-2.11) 0.034
ICU length of stay > 26 h 95(56.2) 235(46.4) 1.49(1.04-2.12) 0.030
Vasoactive drugs 139(82.2) 374(73.8) 1.65(1.05-2.58) 0.029
Erytrocyte transfusion in ICU 75(44.4) 172(33.9) 1.55(1.08-2.23) 0.017
FFP transfusion in ICU 29(17.2) 37(7.3) 2.63(1.50-4.63) 0.001
Platelet transfusion in ICU 72(42.6) 22(4.3) 16.4(9.3-28.9) <0.001
 
The absolute numbers and percentages of patients in the intervention and the reference group are given, the regression derived odds ratios with 
95% CI and exact P values. 
*Marks endpoints that make up the composite endpoint. 
CVVH = continuous venovenous hemofiltration; FFP = fresh frozen plasma; ICU = intensive care unit; SIRS = systemic inflammatory 
response syndrome. 
 
Patients in the intervention group did not endure more stroke, MI, infection, systemic inflammatory 
response syndrome, shock, acute kidney injury, multiorgan failure, death or composite endpoint 
than patients in the reference group (table 3).
The absolute numbers and percentages of patients in the intervention and the reference group are given, the 
regressio  derived odds ratios with 95% CI and exact P values.
*Marks endpoints that make up the composite endpoint.
CVVH = continuous venovenous hemofiltration; FFP = fresh frozen plasma; ICU = intensive care unit; SIRS = 
systemic inflammatory response syndrome.
An early platelet transfusion was significantly associated with the need for postoperative 
vasoactive medication (odds ratio 1.65; 95% CI 1.05 to 2.58); long (above median) mechanical 
ventilation (odds ratio 1.47; 95% CI, 1.03 to 2.11) and long (above median) ICU stay (odds ratio 
1.49; 95% CI, 1.04 to 2.12). Also, patients in the intervention group required erythrocyte (44.4 
vs 33.9%), FFP (17.2 vs 7.3%) and platelet transfusion in the ICU (42.6 vs 4.3%) more often as 
compared to patients in the reference group (table 3). The sensitivity analyses yielded results 
similar to the original analyses.
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Blood loss >500 mL first 12 h 79 (46.7) 290 (57.2) 0.68 (0.47-0.97) 0.033 
Early reexploration for bleeding /tamponade 4 (2.4) 23 (4.5) 0.53 (0.17-1.59) 0.257
Late intervention for tamponade 4 (2.4) 6 (1.2) 1.94 (0.49-7.76) 0.346
Stroke 5 (3.0) 16 (3.2) 1.03 (0.38-2.81) 0.957
Myocardial infarction 25 (14.8) 57 (11.2) 1.40 (0.84-2.34) 0.195
Patients with postoperative infection 35 (20.7) 88 (17.4) 1.25 (0.80-1.96) 0.325
- Mediastinitis 2 (1.2) 1 (0.2) 7.09 (0.75-66.7) 0.087
- Superficial wound infection 1 (0.6) 2 (0.4) 1.48 (0.13-17.0) 0.753
- Pneumonia 4 (2.4) 13 (2.6) 0.87 0.28-2.69) 0.808
- Sepsis 11 (6.5) 23 (4.5) 1.47 (0.69-3.11) 0.318
- Other infections 27 (16.0) 62 (12.2) 1.39 (0.83-2.32) 0.206
SIRS 13 (7.7) 25 (4.9) 1.46 (0.71-3.00) 0.305
Shock 28 (16.6) 67 (13.2) 1.31 (0.79-2.17) 0.299
CVVH de novo 9 (5.3) 19 (3.7) 1.42 (0.61-3.30) 0.411
Multi organ failure 7 (4.1) 16 (3.2) 1.31 (0.53-3.27) 0.561
In hospital mortality 7 (4.1) 13 (2.6) 1.55 (0.61-3.95) 0.354
Composite endpoint 34 (20.1) 89 (17.6) 1.21 (0.77-1.90) 0.407
Ventilation >11h 92 (54.4) 227 (44.8) 1.53 (1.07-2.20) 0.021
ICU length of stay >26h 95 (56.2) 235 (46.4) 1.51 (1.06-2.17) 0.024
Vasoactive drugs 139 (82.2) 374 (73.8) 1.62 (1.04-2.55) 0.034
RBC transfusion in ICU 75 (44.4) 172 (33.9) 1.64 (1.13-2.38) 0.009
FFP transfusion in ICU 29 (17.2) 37 (7.3) 2.80 (1.56-5.00) 0.001
Platelet transfusion in ICU 72 (42.6) 22 (4.3) 18.8 (10.3-34.0) <0.001
 
The results of the first sensitivity analysis in which the logistic regression was adjusted for the covariates “cellsaver blood returned or 
not” and “nadir intraoperative hemoglobin”. The absolute numbers and percentages of patients in the intervention and the reference 
group are given, the regression derived odds ratios with 95% confidence interval and p-values. 
 
CI confidence interval; CVVH Continuous Veno-Venous Hemofiltration; FFP fresh frozen plasma; ICU Intensive Care Unit; RBC red 
blood cell; SIRS systemic inflammatory response syndrome 
 
The results of the fi st sensitiv ty analys s in which the logistic regression was adjusted for the covariates “cellsaver 
blood retur d o  not” and “nadir intraoperative hem globin”. The absolute numbers and percentages of patients 
in the intervention and the reference group are given, the regression derived odds ratios with 95% confidence 
interval and p-values.
CI confidence interval; CVVH Continuous Veno-Venous Hemofiltration; FFP fresh frozen plasma; ICU Intensive Care 
Unit; RBC red blood cell; SIRS systemic inflammatory response syndrome.
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Blood loss >500 mL first 12 h 79(46.7) 290(57.2) 0.67(0.47-0.97) 0.032 
Early reexploration for bleeding /tamponade 4(2.4) 23(4.5) 0.49(0.17-1.44) 0.196
Late intervention for tamponade 4(2.4) 6(1.2) 1.84(0.47-7.31) 0.384
Stroke 5(3.0) 16(3.2) 0.95(0.33-2.74) 0.924
Myocardial infarction 25(14.8) 57(11.2) 1.41(0.84-2.35) 0.195
Patients with postoperative infection 35(20.7) 88(17.4) 1.24(0.79-1.95) 0.359
- Mediastinitis 2(1.2) 1(0.2) 7.29(0.68-78.0) 0.101
- Superficial wound infection 1(0.6) 2(0.4) 1.28(0.11-14.4) 0.840
- Pneumonia 4(2.4) 13(2.6) 0.88(0.28-2.76) 0.820
- Sepsis 11(6.5) 23(4.5) 1.47(0.69-3.11) 0.317
- Other infections 27(16.0) 62(12.2) 1.36(0.81-2.29) 0.239
SIRS 13(7.7) 25(4.9) 1.33(0.63-2.83) 0.451
Shock 28 (16.6) 67 (13.2) 1.25(0.74-2.10) 0.399
CVVH de novo 9 (5.3) 19 (3.7) 1.12(0.45-2.83) 0.805
Multi organ failure 7 (4.1) 16 (3.2) 1.07(0.39-2.93) 0.902
In hospital mortality 7 (4.1) 13 (2.6) 1.31(0.47-3.61) 0.605
Composite endpoint 34 (20.1) 89 (17.6) 1.17(0.74-1.85) 0.511
Ventilation >11h 92 (54.4) 227 (44.8) 1.52(1.06-2.19) 0.024
ICU length of stay >26h 95 (56.2) 235 (46.4) 1.49(1.04-2.15) 0.030
Vasoactive drugs 139 (82.2) 374 (73.8) 1.63(1.04-2.57) 0.035
RBC transfusion in ICU 75 (44.4) 172 (33.9) 1.62(1.11-2.36) 0.012
FFP transfusion in ICU 29 (17.2) 37 (7.3) 2.74(1.52-4.94) 0.001
Platelet transfusion in ICU 72 (42.6) 22 (4.3) 19.9(10.6-37.2) <0.001
 
The results of the second sensitivity analysis in which the logistic regression was adjusted for the covariate “EuroSCORE” besides for 
“cellsaver blood returned or not” and “nadir intraoperative hemoglobin”. The absolute numbers and percentages of patients in the 
intervention and the reference group are given, the regression derived odds ratios with 95% confidence interval and p-values. 
 
CI confidence interval; CVVH Continuous Veno-Venous Hemofiltration; FFP fresh frozen plasma; ICU Intensive Care Unit; RBC red 
blood cell; SIRS systemic inflammatory response syndrome 
 
The results of the second sensitivity analysis in which the logistic regression was adjusted for the covariate 
“EuroSCORE” besides for “cellsaver blood returned or not” and “nadir intraoperative hemoglobin”. The absolute 
numbers and percentages of patients in the intervention and the reference group are given, the regression derived 
odds ratios with 95% confidence interval and p-values.
CI confidence interval; CVVH Continuous Veno-Venous Hemofiltration; FFP fresh frozen plasma; ICU Intensive Care 
Unit; RBC red blood cell; SIRS systemic inflammatory response syndrome
Discussion
Main findings
In this study, no statistically significant difference was observed with regard to reinterventions for 
bleeding, stroke, MI, infections, systemic inflammatory response syndrome, shock, acute kidney 
injury, multi organ failure, death or composite endpoint between patients who received a single 
early platelet concentrate and those that did not. However, patients in the intervention group 
experienced less blood loss and required postoperative vasoactive medication, long mechanical 
ventilation, long ICU stay, erythrocyte, FFP and platelet transfusion in the ICU more often as 
compared to patients in the reference group.
Interpretation
The observed correlations between early platelet transfusion and less blood loss; longer 
postoperative mechanical ventilation; longer intensive care stay and higher rate of administration 
of vasoactive drugs in the ICU, might be explained by a causal effect of the platelet transfusion. 
For example, the fact that patients in the intervention group experienced less blood loss 
postoperatively could be due to the perioperative platelet transfusion. In the case of the 
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vasoactive drugs, it may be possible that in the intervention group more patients suffered  from 
vasoplegia, and therefore required vasoactive support more often compared to the reference 
group. Vasoplegia as the indication, and thus possible causal explanation, of the higher risk 
of vasoactive medication would be in agreement with previous findings of others. First of all 
it would be consistent with the finding that patients undergoing cardiac surgery with the use 
of CPB commonly encounter vasoplegia for which pharmacological support, in the form of 
vasoactive drugs, is needed.30,31 More importantly it would be in agreement with the correlation, 
demonstrated by others, between platelet transfusion and an increased risk of vasoplegia after 
cardiac surgery.16 In our data, the diagnoses shock, SIRS and sepsis, were equally distributed among 
the groups, and are therefore not a plausible explanation for the difference in vasoactive drug 
need. This presumed higher rate of vasoplegia may further explain our finding that intraoperative 
platelet transfusions are associated with longer mechanical ventilation and intensive care stay.
However, although propensity score matching resulted in comparable baseline characteristics 
of both groups, it is also possible that the observed association is due to residual confounding, 
which is not visible in the measured baseline characteristics. Moreover, most of the observed 
associations are not strong, so they might also be explained by random chance and then it 
would be incorrect to reject the null hypothesis (type I error). We did not adjust the p-values 
in tables 2 and 3 for multiple testing, although we analysed multiple endpoints. If Bonferroni 
correction had been used, the associations between an early platelet transfusion and amount 
of blood loss, postoperative mechanical ventilation; intensive care stay, vasoactive drugs and 
erythrocyte administration in the ICU would no longer be considered statistically significant. 
However, the associations between an early platelet transfusion and postoperative plasma and 
platelet transfusions in the ICU would remain statistically significant after Bonferroni correction. 
With considering the results of a Bonferroni correction, we reduce the chance on making type I 
errors, but risk missing subtle associations with potential clinical importance.
In our study, an early platelet transfusion did not seem to reduce the need for reinterventions 
for bleeding or tamponade, but was associated with a lower blood loss and a higher rate of 
erythrocyte, plasma and platelet transfusions in the ICU. The fact that no statistically significant 
association was observed between an early platelet transfusion and early re-exploration for 
bleeding and/or tamponade and late intervention for tamponade, might be explained by a lack 
of statistical power. A possible explanation for the higher rate of postoperative transfusions, is 
that once one transfusion has been administered, the threshold for subsequent transfusions 
is lowered. Theoretically, a difference in preferences and convictions of treating physicians 
regarding transfusions, resulting in comparable patients receiving different treatment, could 
explain the higher transfusion rate in the ICU. However, in practice physicians who made the 
decision to transfuse platelets in the OR were generally not responsible for the treatment in the 
ICU. Finally, in addition to all the above-mentioned considerations, it may also be the case that 
one postoperative endpoint influenced another postoperative endpoint, but this could not be 
verified in this database. For example, besides the early platelet transfusion, the plasma and 
platelet transfusions given in the ICU may also have contributed to the lower blood loss in the 
intervention group.
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Comparison with previous studies
Several other studies have analyzed the association between platelet transfusions and morbidity 
and mortality in cardiac surgery with varying findings. Our results are in contrast with the studies 
that report that transfusion of platelets increases the risk of serious adverse outcomes.17,20,21,32 There 
are various possible explanations for the discrepancy between the findings of these studies and 
our results. First, not in all studies appropriate and sufficient adjustment of potential confounding 
factors, like use of aprotinin or concomitant erythrocyte and plasma transfusions, was applied. 
Second, in contrast to these four studies, we aimed at analyzing patients who only received one 
platelet unit and no other blood product shortly after end of CPB while still in the operating room. 
We focused on these patients because in these patients the indication for the platelet transfusion 
can be debatable and because these patients are most comparable to patients who received 
no transfusion. Third, a considerable part of the platelet units examined in these studies was not 
leukocyte-reduced and the vast majority of the units we studied were leukocyte-reduced.
Our results are consistent with several studies that showed no correlation between platelet 
transfusion and adverse outcomes like infection, low cardiac output syndrome, MI, stroke, renal 
failure, sepsis, and mortality.15,18,33 One study ascertained an association between perioperative 
platelet transfusion and an increased risk of surgical re-exploration for bleeding, which we did 
not observe. However the remaining results of this study, regarding postoperative mortality, 
composite endpoint, infectious, cardiac, renal, pulmonary and neurologic complications, were 
similar to ours.19
Strengths and limitations
To the best of our knowledge, this study is the first to analyze the effect of a single platelet 
transfusion in a broader cardiac surgery population, consisting both of patients who underwent 
coronary artery bypass graft and those undergoing (concomitant) valve procedures. Besides we 
report not only on adverse outcomes, but also the intended effect of the transfusion, which is 
to prevent and/or stop excessive bleeding. Hereby we aimed at obtaining the overall picture 
of all potential consequences for a clinician who is considering a platelet transfusion for a 
cardiac surgery patient. A potential concern of our study is the 16-yr period that was studied, 
because multiple developments occurred both in blood banking and in cardiac surgery and 
anesthesiology in this period. However, by including year of surgery in the propensity score we 
strongly reduced the potential confounding impact of the developments. Furthermore, to the 
extent of our knowledge, we are the first to study patients who received just a single early platelet 
transfusion in absence of concomitant transfusion of other blood products, which precludes 
potential influence of erythrocyte or FFP transfusions on the outcomes. Another strength of 
our study is that we adjusted for confounding by indication by propensity score matching. By 
using propensity score matching we were able to identify the patients, out of the 17,747 selected 
patients, who received no early transfusion who were most comparable to the patients transfused 
with a single early platelet concentrate. A limitation of our study is that despite accurate propensity 
score matching residual confounding, by unknown confounders, cannot be completely ruled 
out. The large comprehensive cohort of 23,860 patients allowed the analysis of sufficient patients 
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numbers after strict selection of the specific population of interest. Although for some endpoints 
the 95% confidence interval was relatively wide, which may be partially caused by a lack of power. 
Since the database was extensive and detailed, it was possible to include the factors that were 
considered relevant in the propensity score. Furthermore since the data had been collected prior 
to and therefore independently of the present study, information and selection bias are minimum.
In this study, cardiac surgery patients receiving platelet transfusion in the operating room 
experienced less blood loss and required vasoactive medication; prolonged ventilation; 
prolonged intensive care and blood products more often postoperatively. However, our findings 
further show that an early platelet transfusion was not associated with other serious adverse 
outcomes like thromboembolic complications, infections, organ failure, in-hospital mortality and 
reinterventions for bleeding.
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Summary and General Discussion
Preoperative risk assessment in cardiac surgery
The EuroSCORE I, developed in 1999, has been used as an important risk model in cardiac         
surgery, its successor EuroSCORE II was presented in 2012
We performed a validation study to assess whether or not the EuroSCORE II was a valid risk 
model in a Dutch cardiac surgery centre.
The EuroSCORE II outperforms its predecessor in a Dutch single center validation study, 
with as exception emergency surgery
In the second chapter of this thesis we presented a prospective validation study of the EuroSCORE 
II. This study validated the EuroSCORE II in a complete cohort undergoing all types of cardiac 
surgery and also aimed at validating the EuroSCORE II in subgroups according to type of surgery 
and whether or not emergency surgery was performed.
Our results show that in a Dutch hospital, the EuroSCORE II had a more accurate calibration and 
discrimination than its predecessor the EuroSCORE I. An exception to this were patients who 
underwent emergency surgery.
In that category, the EuroSCORE II did not perform better than the EuroSCORE I, it underestimated 
mortality. This is in agreement with a meta-analysis of 22 studies involving 145,592 cardiac surgery 
procedures which also found that the EuroSCORE II performs less accurate in high risk patients 
and in emergency surgery.1 Apparently in emergency surgery and in high risk patients, unknown 
patient variables which are not included, neither in the EuroSCORE I nor in the EuroSCORE II 
are more important for accurate prediction of peri-operative mortality. Future studies should 
therefore focus on identifying the patient variables most important for predicting outcome in 
emergency surgery and develop separate risk models for these high-risk patients.
In emergency surgery, factors predicting patient outcome could be of more logistical nature than 
in patients who undergo elective surgery. For example, the time to diagnosis, time from diagnosis 
until the moment of surgery, and the local experience with emergency surgery. To develop a valid 
risk model for emergency patients, these factors should be taken into account, as well as blood 
loss before surgery, the use of anti-coagulant drugs and cardio-pulmonary resuscitation and its 
duration. For high risk patients, a more comprehensive risk model with more attention for the 
severity of co-morbidities could improve prediction.
Until a valid risk model for emergency patients is developed, the EuroSCORE I as well as the 
EuroSCORE II should not be used in emergency patients neither to council patients nor to inform 
their next of kin because they are unreliable. Risk prediction of these patients should be based on 
their individual symptoms and co-morbidity until a more accurate risk model is in place.
Implementing risk models in daily practice before validating them in a local population should 
not occur as different genetic backgrounds, population lifestyles or local treatment regimens 
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in a particular patient population (assuming the validation study was carried out correctly), 
results should be published, and an adjusted risk model should be developed, designed to the 
peculiarities of the local population.
This is especially important because risk models are more and more used for patient counseling 
and as tools to assess if a particular patient is eligible for surgery and if open heart surgery or a 
trans-catheter procedure is more suited.2,3 
It is also important to realize that a risk model is not finished when its first version is presented 
but that they require updating. Nowadays risk models are more and more used for comparing 
the quality of care providers by both patients as well as health care  regulators and it is important 
that they stay accurate over time.4 As seen with the EuroSCORE I model, the calibration and 
discriminative powers of a risk model will diminish over time, due to progress in medical 
techniques. Therefore, the performance of risk models like the EuroSCORE II model should be 
assessed regularly and if necessary adjustments should be made.
The EuroSCORE II and other risk models focus primarily on mortality as outcome measure, but 
post-operative morbidity is an equally important outcome as serious morbidity diminishes 
quality of life and is a known cost item. Separate risk models should be developed to predict the 
risk of different co-morbidity after cardiac surgery.
Transfusion thresholds in cardiac surgery
In 2008 a study showed that a relative hemoglobin decrease of more than fifty percent 
was associated with adverse outcomes after cardiac surgery.
These results were neither confirmed nor contradicted.
Our results confirm that an intra-operative hemoglobin decrease of fifty percent or more 
is associated with more adverse outcomes after cardiac surgery.
  
In the third chapter of this thesis we presented a study in which we analyzed the effect of a 
hemoglobin decrease of fifty percent during cardiac surgery. We performed this study because 
in 2008 a Canadian study found that not only the absolute hemoglobin level but also the relative 
hemoglobin decrease should be taken into account when the decision to transfuse red cells is 
made and these results were never confirmed nor contradicted.5
Our results show that patients who do not reach the transfusion threshold of seven g/dL but do 
suffer from a hemoglobin decrease of more than fifty percent compared to their pre-operative 
hemoglobin indeed have worse postoperative outcome. Another study, similar in design, has also 
confirmed these results.6 Results of these three studies imply that it might be beneficial to include 
this degree of intraoperative Hb decrease in the decision to transfuse.
Current transfusion thresholds in cardiac surgery patients are in the range of seven to eight g/dL 
depending on age and severity of co-morbidity.7,8 It is not known in which situations the benefits 
of a transfusion outweigh the side effects. As this differs between individual patients and whether 
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transfusion trigger for all patients. Accordingly, optimization of the transfusion trigger should take 
individual factors into account.9,10
An often used strategy in patients  with acute coronary disease undergoing cardiac surgery is 
to transfuse until the hemoglobin level is above eight g/dL, if the patient remains symptomatic 
(hypotension, wall motion abnormalities on echography, elevated ST segments and/or other 
ECG deviations), then red cell transfusions up to a hemoglobin level of ten g/dL is advised.11 The 
evidence base for this policy is limited and based on large observational studies. Future studies 
should be performed to establish individualized transfusion triggers for patients with acute 
coronary syndromes.11,12
For patients suffering from stable chronic coronary disease undergoing elective cardiac surgery 
a minimum hemoglobin level of seven to eight g/dL is deemed safe, as was shown in different 
randomized studies.13–15 But in none of these studies the extent of the coronary lesions has been 
properly assessed and taken into account when determining the desired Hb level. The extent of 
coronary lesions is potentially also related to efficacy of red cell transfusions because it may be 
possible that more extensive coronary lesions impair the delivery of oxygen to tissues (DO2) in a 
more extended way, leading to a higher transfusion trigger in these patients.
Further optimization of personalized transfusion triggers could be achieved by including 
more patient characteristics besides the hemoglobin level and severity of co-morbidity. These 
characteristics could include smoking (because of the effects of chronic carbon monoxide 
exposure), ejection fraction (to take the adequacy of the DO2 into account), pre-operative 
coagulation parameters (because of the higher chance of extended bleeding while having an 
impaired coagulation), and the extent of the coronary disease. Future studies should look into 
the possibility of implementing these factors and other possible (bio-)markers in a transfusion 
trigger and evaluate whether or not this leads to improved transfusion policies with practical 
applicability.
Intra-operative anemia in cardiac surgery
With decreasing intraoperative hemoglobin levels (compared to preoperative hemoglobin 
levels) during cardiac surgery, there is an increase in adverse events.
A single red cell unit given to increase the hemoglobin level above 8 g/dL did not 
influence post-operative outcomes when compared with patients who did not receive a 
transfusion. This means that the transfusion in these patients was useless.
In chapter four we presented a study in which we evaluated anemia in Jehovah’s witnesses and 
observed that with the decrease of hemoglobin levels an increase in adverse effects occurred. 
We composed a group of patients who received one red cell transfusion, matched and compared 
them with two similar groups of patients who did not receive a red cell transfusion. One group 
consisted of Jehovah’s witnesses and the other one of non- Jehovah’s witnesses. Our findings 
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patients compared to matched Jehovah’s witnesses and to non-Jehovah’s witnesses receiving no 
transfusion. This suggests that the red blood cell transfusion should have been avoided.
Studying the effects of anemia independently of red cell transfusions is difficult because the 
treatment of anemia consists of a red cell transfusion. Red cell transfusions are known to have 
adverse effects of their own and some of those adverse effects are comparable to the adverse 
effects of anemia.6,16–18
We tried to preclude this by examining intra-operative anemia among Jehovah’s witnesses, 
because Jehovah’s witnesses, due to their religious beliefs refuse to receive any blood products. 
But including Jehovah’s witnesses in a study can introduce bias when they are compared to non-
Jehovah’s witnesses because Jehovah’s witnesses often receive a more extensive pre-operative 
preparation, sometimes including erythropoietin and iron supplements. Also, the selection 
regarding which patient is eligible for surgery is stricter and the surgeon may operate with more 
caution to prevent blood loss during surgery. So, statistical analyses of these studies should be 
carried out with caution, the non-Jehovah’s witnesses which are compared to Jehovah’s witnesses 
should be carefully matched, which we did by using propensity scores.
Previous studies showed that Jehovah’s witnesses can be operated on safely. Some findings 
suggest that patient outcomes are better after thoracic surgery without the use any of blood 
products (bloodless surgery).19–21
These previous results combined with our results suggest that bloodless cardiac surgery is safe 
in selected patients. Results regarding emergency surgery and/or surgery in which hemoglobin 
decrease exceeded 50% of the base line hemoglobin level in Jehovah’s witnesses are lacking, 
although it is likely that the outcome in these cases is worse.
Formation of allo-antibodies and red cell storage time
Allo-antibody formation is a side effect of red cell transfusion
Genetic and environmental factors may increase RBC allo-immunization risks, including a 
possible role of storage interval of RBC.
The formation of anti-K antibodies was not associated with duration of red blood cell 
storage time of K-positive transfusions to K-negative patients
In chapter five we presented a study examining the relation between allo-antibody formation 
after red cell transfusion and the storage time of the transfused red cells. Outside the human 
body red cells intended for transfusion are stored up to 35-42 days dependent on the storage 
solution. In our study we analyzed immunization against incompatible K positive red blood cells 
in a patient population with divergent disease entities. We identified the storage time of the 
immunizing and the non-immunizing K positive red cell units. We did not find an association 
between the storage time of red cells and allo-antibody formation.
Research into the origin of allo-antibodies is of utmost importance because alloimmunization 
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hemolytic reactions. Also, the occurrence of alloimmunization is not a rare one as allo-antibody 
formation occurs in 2-10 % of all cardiac surgery patients.22–25
At least 30 RBC antigens can evoke antibodies after incompatible red cell transfusions, but some 
antigens such as Rh and K antigens are more immunogenic than others. A previous study showed 
no association between the storage time of red cells and the formation of anti-D antibodies in 
humans, but this study did not identify the ‘immunizing’ unit.26 Therefore this study could not 
analyze the association between the storage time of the red blood cells which actually induce the 
allo-antibodies and the incidence of alloimmunization. In our study we were able to do so and 
found no association as was previously suggested in mouse models.27
Limitations of our study were that the amount of ‘very old’ units analyzed in our study was 
confined and so an association between ‘very old’ red blood cells and alloimmunization could 
not be excluded and the same is true for the ‘very fresh’ red cells.
Nevertheless, in agreement with a multitude of studies analyzing the effect of storage time on 
other clinical and in vitro outcomes we did not find an association between the storage time and 
adverse outcomes, making it unlikely that such an association exists.28,29
Platelet transfusion in cardiac surgery
Platelet concentrates are relatively often transfused during cardiac surgery because of the 
use cardiopulmonary bypass and pre-operative antiplatelet drugs.
Conflicting results have been reported regarding the effects of platelet concentrates on 
clinical outcomes.
We found that patients who received one platelet concentrate experienced less blood 
loss, compared with similar patients who received none. Patients who received one 
platelet concentrate required more often vasoactive medication, prolonged ventilation, 
prolonged intensive care stay and more blood products postoperatively.
In chapter six we assessed the independent association between a single platelet transfusion, 
transfused during cardiac surgery, and bleeding and adverse postoperative outcomes. Our 
results show that a single platelet transfusion was not associated with more mortality, organ 
failure, infections, thromboembolic complications and re-interventions. Patients who did receive 
a single platelet transfusion experienced less postoperative blood loss compared with similar 
patients who received no platelets. However, they did require more vasoactive medication and 
received more erythrocytes and plasma postoperatively, also they stayed longer on the ICU and 
were longer on ventilatory support.
In contrast to red cell transfusions, in cardiac surgery there is no platelet count which serves as 
transfusion trigger for a platelet transfusion. If patients receive platelets it is often after being 
weaned from the cardiopulmonary bypass, and after neutralization of the heparin so damage 
by the extracorporeal circuit can be avoided. Platelets are generally administered when bleeding 
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concentrates, tranexamic acid and plasma products (Fresh frozen plasma or Omniplasma, a 
solvent/detergent plasma). All of the above explains why platelet transfusion rates differ greatly
between different centers.30–34
To assess whether or not a platelet transfusion is indicated during cardiac surgery, viscoelastic 
point of care tests like the TEG® or the Rotem® are often used. The advantage of these test above 
standard coagulation test is that they have a shorter turn-around time in a clinical setting where 
timely decision on coagulation interventions are a necessity.35,36 A recent review showed that 
transfusion algorithms based on point of care testing lead to a reduction in the amount of 
blood products transfused with no adverse effects on mortality, stroke, prolonged intubation, 
emergency re-operation for bleeding or length of stay (both ICU as in-hospital).37 This implies that 
current point of care testing may reduce the amount of blood products transfused.
With ameliorating techniques, the capabilities of point of care tests and thrombo-elastography 
will expand. Future techniques should be able to detect the nature of coagulopathies and specific 
clotting deficits even faster. Also, it could be feasible not only to perform viscoelastic point of care 
tests when a bleeding does occur but also as a routine monitoring tool during more difficult 
surgeries. This way deficiencies in clotting parameters could be treated before the bleeding 
occurred possibly resulting in a clinical benefit for the patients.
Not only the use of cardiopulmonary bypass but also the use of anti-platelet drugs by patients 
undergoing cardiac surgery increases platelet dysfunction and can contribute to bleeding 
necessitating more transfusions.38
Patients who use anti-coagulant drugs to prevent coronary artery blockage are more prone to 
platelet transfusions especially when these drugs are continued until surgery.39 Over the last 
decade dual anti-platelet therapy (DAPT) has been prescribed to a growing patient population. 
DAPT treatment, existing of a regime with aspirin combined with an adenosine diphosphate 
P2Y12 receptor antagonist (P2Y12 inhibitors) like clopidogrel has been proven to be beneficial in 
patients with acute coronary syndromes and ischemic cardiomyopathies.39
Whether DAPT treatment should be (dis-) continued until the day of surgery is still uncertain. 
Continuing DAPT treatment could be beneficial because it is likely to prevent additional 
thrombotic events but it also can induce more bleeding complications during surgery. There is 
sufficient evidence proving that continuing aspirin alone during the peri-operative period does 
not lead to an increase in postoperative bleeding but could lead to more platelet transfusions.40,41 
With regard to P2Y12 inhibitors current guidelines, updated in 2012, advice that these drugs 
should be discontinued several days before cardiac surgery.42 Nevertheless although some studies 
conclude that stopping these drugs is associated with reduced bleeding, blood transfusion and 
reoperation, others find that continuing P2Y12 inhibitors leads to les thrombotic complications. 
Maybe future studies can find more definite answers, until then continuing or stopping DAPT 
treatment should be evaluated for each individual patient.42–44
The future of research, transfusions and cardiac surgery
In this last section we address some aspects regarding the future of transfusion medicine 
and cardiac surgery. Cardiothoracic surgery is not without risk and patients can suffer from 
considerable blood loss due to the nature of surgery, the use of heart lung machines, pre-
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existent and/or drug induced coagulation disorders, etc. This means that a notable part of the 
patients undergoing cardiac surgery receive blood products which have considerable side 
effects of their own. Future research should generate knowledge on how to prevent bleeding 
and how to optimize coagulation perioperatively. Topics which should be examined more closely 
are for example, the optimization of anticoagulant drug use perioperatively, further reduction 
of the volume of heart lung machines and a more effective use of point of care coagulation 
tests during surgery. Nevertheless, transfusion of blood products will remain necessary for a 
number of patients. Therefore, future research should also focus on identifying which patients 
will benefit from transfusions and further examine the most suitable transfusion trigger. Another 
issue that needs further investigation are the side effects of red cell transfusions like for example 
alloimmunization.
A possible solution to the side effects described above would be substitution of erythrocyte 
transfusion by artificial oxygen carriers. In the search for artificial oxygen carriers, three different 
concepts have been pursued over the years. Chemical O2 and CO2 transporters, only to use in 
mechanical ventilated patients, second artificially modified Hb derived from human, bovine, 
swine or even worm hemoglobin and third the ex vivo culture of erythrocytes lacking selected 
antigens.45,46 Nowadays, only one (bovine) product suitable for humans is registered, and it is 
only registered in South Africa.47 The use of this oxygen carrier comes with adverse effects on 
the cardiovascular system like vasospasms and/or vasoconstriction and therefore registration 
in the European Union and the United States of America has not been granted.48 Biotechnical 
limitations which were difficult to overcome have slowed the research in this area for some time, 
but recently, the search of artificial blood products seems to flourish again.45,49 Nevertheless, 
many challenges will be encountered before artificial oxygen carriers can replace red blood cell 
transfusions, and it is unlikely that complete replacement of allogenic red cell transfusions will be 
realized because there are too many disadvantages like for example the short lifespan of artificial 
oxygen carriers. But a supplemental role for artificial oxygen carriers should be further examined. 
They could be used for example in ex vivo perfusion of organ grafts before transplantation, as 
the first human liver transplantation after machine perfusion with artificial oxygen was recently 
performed.50 Other uses, for example as a bridge to transfusion, or to surpass severe hemodilution 
should be further investigated.
Another topic of future research should be developing a better way to predict the need for 
red cell transfusions in individual patients. This could be achieved by composing a risk model 
using variables of which it is known that they influence oxygen delivery, such as pulmonary 
and cardiac conditions among others. In the past such risk models have been constructed, 
but the generalizability of these models did not suffice as these models were not constructed 
prospectively and thus based on deprecated data or were composed in a selected population 
which demised their generability.51–53
Identifying patients at risk of receiving a red cell transfusion during cardiac surgery has the 
advantage that some of these patients can be better prepared before surgery, for example in 
the same way that Jehovah witnesses are prepared. Iron supplements, erythropoietin and the 
emphasis on meticulous surgical coagulation could help prevent red cell transfusions in these 
patients. The annotation must be made that, the goal of the extended measures mentioned 
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above is improving the patient’s clinical outcome and not reducing the number of transfusions 
per se. Treating cardiac surgery patients who have a greater chance at receiving a red cell 
transfusion with additional hemoglobin increasing therapies could be beneficial for some. But 
when implementing these therapies (for example as standard treatment in a PBM) one should 
realize that every treatment has its own side effects. For example, erythropoietin increases blood 
viscosity, and some studies report increased risk of infection in patients who are treated iron 
supplements.54 So ideally a preemptive strategy to minimize the chance on red cell transfusion 
should be tailor made to the needs of the patient.
As with the preemptive measures mentioned above a ‘tailor made’ transfusion trigger could be 
more beneficial for patients then the current transfusion guidelines used. One can imagine that 
a more personalized transfusion threshold could prevent needless transfusions in patients who 
don’t require them and also it could help determining which patients will benefit from blood 
products. Whether or not this will lead to better clinical outcomes should be assessed, preferably 
in a randomized control trial in which one group of patients will be transfused according to current 
transfusion guidelines and another group which will be transfused according to a personalized 
transfusion trigger. This personalized transfusion trigger should consist of information about the
hemoglobin concentration of the patient complemented with patient characteristics mentioned 
when we discussed chapter three.
Furthermore, to improve a more individualized transfusion policy in the future it may be feasible to 
include advanced O2 measurements in transfusion algorithms. With the development of cerebral 
tissue oxygenation devices, like INVOS©, the oxygen saturation of the brain can be measured 
directly. Using these devices, red cell transfusion could be better adjusted to the actual oxygen 
demand during surgery. A randomized clinical trial published results which favored the use of 
these devices in guiding the decision making process with regard to red cell transfusions.55 In this 
trial patients were randomized in one of two groups, the first group had a transfusion algorithm 
mostly based on cerebral oximetry values while the other group had a conventional algorithm 
based on hematocrit values. The results show that the in the cerebral oximetry group less red 
cell transfusions were prescribed perioperatively while there were no differences in outcome 
between both groups. Nevertheless when considering a red cell transfusion, values from cerebral 
oximetry always have to be interpreted with regards to the clinical situation of the patient.56,57
Maybe the best way to personalize the transfusion trigger lies in the development of a method in 
which intra- mitochondrial oxygen levels could be directly measured in the critical organs during 
surgery. This way oxygen delivery and the oxygen consumption could be best adjusted to each 
other. Such a device is currently under study in the LUMC, AMC and Erasmus MC.58 This research 
focuses on validating this method of cellular O2 measurement and when proven beneficial, 
transfusions protocols should be adjusted accordingly.
Some have implied that a prolonged storage time of red cells diminishes their quality and that 
a shorter storage time should be established to ensure the quality, effectivity and safety of 
transfused red cells. It is true that the quality of red cells alters over time because of changes 
that occur in the erythrocyte during storage, like a decrease of glucose, 2-3 diphosphoglycerate, 
adenosine triphosphate and an increase of potassium in the solvent. These changes combined 
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are called the storage lesion and is known to be partly reversible when the erythrocyte is ‘back 
in vivo’.59
An extensive number of studies has been published about the clinical implication of the storage 
lesion. Most well executed studies however, did not find an association between storage time 
and increased morbidity and/or mortality.28,29 In the recent years several large international 
randomized clinical trials, performed in different patient groups like as ICU patients, children and 
cardiac surgery patients published their results, also showing that prolonged storage time within 
the current ranges of storage is not associated with adverse clinical outcomes of transfusion 
recipients.29
It is hard to determine when there is enough evidence to accept that there is no causal effect of 
an intervention on patient outcomes but in the case of red cell storage time there is a convincing 
amount of evidence suggesting that there is no benefit when fresher red cells are transfused. 
Therefore, there is no need to perform more studies on the effect of storage time of red cells on 
clinical outcomes.
Other measures that could be taken to prevent bleeding complications and the transfusion 
of blood products in cardiac surgery patients are optimizing coagulation and minimalizing 
hemodilution. Optimizing coagulation can be achieved by meticulous surgical coagulation but 
also by sensible use of pro-coagulant drugs like desmopressin and anti-fibrinolytics like tranexamic 
acid. Future research must be done to find the optimal dose and timing of administration of these 
drugs, in order to be included in updated guidelines. The same goes for P2Y12 inhibitors and the 
interval before surgery in which they should be stopped. In clinical practice a wash out period 
of five to seven days is often used, but there is a large inter-individual variability in response 
to P2Y12 inhibitors. Point of care testing as a pre-operative screening tool could help to find 
the ideal timing to stop these drugs before surgery based on platelet reactivity.43 Improving the 
current techniques for point-of-care coagulation testing and including these improved tests in 
transfusion algorithms could also lead to better clinical outcomes because it could accelerate 
diagnostics and proper treatment.
Hemodilution could be decreased if future heart lung machines will become available requiring 
a smaller extracorporeal volume.
To conclude, every well-constructed study has its importance if it is carried out correctly.  Every 
reliable study contributes to better understanding of a problem, however small this contribution 
may be. For every acceptance or rejection of a hypothesis a growing body of evidence is formed 
to guide us in the right direction. Therefore, it is counterproductive to rely on personal clinical 
experience alone as this is restricted to a limited set of observations and important new evidence 
can be missed, which can lead to inferior and outdated treatment regimes.
The intent of this thesis was to shed light on when transfusing blood products is the right decision 
during cardiac surgery. As every blood transfusion has its risk on adverse events, every decision 
to transfuse must be based on reliable scientific evidence. Therefore, more research needs to 
be performed, more evidence needs to be gathered and more awareness regarding the risks of 
transfusions needs to be spread until we are certain that ‘primum non nocere’ is a fact with regard 
to transfusion medicine in cardiac surgery.
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What is known?
The EuroSCORE I (1999) has been an important risk model in cardiac surgery, its successor 
EuroSCORE II was presented in 2012
Hemoglobin decrease > 50% during cardiac surgery is potential harmful, but current 
transfusion guidelines are based on absolute hemoglobin levels, gender and selective co-
morbidity
Extensive blood loss can be detrimental but on the other hand red cell transfusions can 
have detrimental side effects, which one is the cause of adverse clinical effects is almost 
impossible to determine
Allo-antibody formation is a known side effect of red cell transfusions, approximately
5% of all cardiac surgery patients develop red cell antibodies
Platelet concentrates are relatively often transfused during cardiac surgery because of the 
use of heart lung machines and the use of anti-platelet drugs before surgery.
What does this thesis add?
The Euroscore II outperforms its predecessor in a Dutch single center validation study, 
both EuroSCORE I and II are not reliable enough in emergency surgery
An intra-operative hemoglobin decrease of 50% or more leads to more adverse outcome 
after cardiac surgery
Intra-operative anemia is associated with more adverse outcomes
Transfusion of a single red blood cell concentrate does not seem to influence these 
outcomes
It is not likely that there is a causal relationship between allo-antibody formation and 
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Summary
Cardiac surgery is one of the fastest evolving fields in medicine. With improved techniques and 
the ever aging population, increasing numbers of patients with co-morbidities are undergoing 
cardiac surgery. Before cardiac surgery, it is important to weigh the benefits against the risks 
of surgery. The EuroSCORE I model had been an accurate tool to predict mortality after cardiac 
surgery. But over the years the accuracy of this model seemed to decrease. Therefore an updated 
version, the EuroSCORE II was created. In this thesis we validated the EuroSCORE II in a Dutch 
population of patients undergoing cardiac surgery and found that the EuroSCORE II model 
indeed outperformed its predecessor in the majority of patients. An exception to this was found 
in patients with very high preoperative risks and in emergency situations. For these patients 
the EuroSCORE did not predict mortality accurately and a new risk model would need to be 
developed for this category. For the remaining patient conditions the EuroSCORE II model is a 
reliable tool to predict mortality due to cardiac surgery.
Cardiac surgery can lead to significant blood loss which has led traditionally to high amounts of 
patients being treated with transfusion of allogeneic red blood cells. Over the past decades more 
conservative transfusion triggers have been implemented, trying to minimize the exposure to 
red cell transfusion and their possible side effects. But it is not known which Hb decrease can be 
safely tolerated and it is likely that this will differ between patients. A previous study in cardiac 
surgery patients assessed possible adverse events in patients with a Hb decrease of fifty percent 
or more during cardiac surgery. This study showed that such excessive hemoglobin decreases 
were associated with more postoperative adverse outcomes like acute kidney injury, myocardial 
infarction and mortality. The results of that study had not been confirmed nor contradicted.
We performed a study similar in design in a Dutch cohort. Our results also show that patients who 
did not reach the transfusion threshold of 7 g/dL but who did suffer from an intraoperative Hb 
decrease of fifty percent or more indeed had more postoperative adverse events compared to 
patients who had an intraoperative Hb decrease less than fifty percent. These results imply that it 
might be beneficial to include the degree of intraoperative Hb decrease in the decision when to 
transfuse so a more personalized transfusion trigger can be composed.
One of the hardest questions to answer in transfusion medicine is when do the benefits of a red 
cell transfusion outweigh its possible side-effects in patients suffering from anemia. Studying 
the effects of intraoperative anemia independently of red cell transfusions is difficult, not only 
because it is associated with many other detrimental factors but also because intraoperative 
anemia is treated with red cell transfusions which in itself also can cause adverse effects. With the 
aim to study the effect of red cell transfusion independent of the effects of anemia we examined 
Jehovah’s witnesses with intraoperative anemia and compared them with matched non-
Jehovah’s witnesses (patients with similar characteristics) who did receive one red cell transfusion 
intra-operatively. There were no differences between the Jehovah’s witnesses and the transfused 
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non-Jehovah’s witnesses with regard to postoperative adverse events. This suggest that the red 
cell transfusion may have been redundant and that more red cell transfusions could be avoided if 
non-Jehovah’s witnesses received the same pre- and intra-operative care as Jehovah’s witnesses.
One of the possible adverse effects of red cell transfusions is the formation of allo-antibodies 
against red blood cells of the donor. The consequences of this so called red cell allo-immunisation 
can vary from logistic inconvenience when obtaining compatible blood to acute and delayed 
hemolytic transfusion reactions. Why one patient develops red cell antibodies to an incompatible 
red cell transfusion and another patient does not, is not known. One of the factors that could 
influence the formation of allo-antibodies is the storage time of red cells, as was the case in a 
mouse model. One could hypothesize that with a prolonged storage time red blood cells become 
more immunogenic and are more prone to causing allo-antibody formation. To assess whether 
this is true or not we compared the incidence of anti-K formation in patients who received K 
incompatible blood with different storage times (14, 18 and 21 days were used as cut off-point 
for ‘old’ versus ‘fresh’ red cells). We did not find any association between storage time and the 
formation of anti-K, which was also confirmed in the analysis in which we took the storage time 
of the concomitantly transfused K- red blood cells into account. Our results imply that the storage 
time of transfused red cells does not play a role in the formation of allo-antibodies. Which factors 
are most important in the formation of allo-antibodies and if these factors contribute equally for 
the different RBC antigen specificities remains a subject for further research.
Conflicting results have been reported on the effect of platelet transfusions in patients with 
various clinical conditions. In the last chapter of this thesis we analyzed the independent effects 
of a single platelet transfusion in patients undergoing cardiac surgery. We selected patients 
who received one platelet concentrate shortly after the cardiopulmonary bypass and no other 
blood products. These patients were matched 1:3, using propensity score matching, to patients 
who did not receive any blood products during surgery. We found that patients who received a 
platelet concentrate experienced less blood loss but more often required vasoactive medication, 
prolonged ventilation, prolonged intensive care stay, and other blood products postoperatively. 
In the literature vasoplegia has been mentioned as a possible side-effect of a platelet transfusion 
and vasoplegia could also be the cause for the use of more vaso-active medication, the longer 
ICU stay and the prolonged ventilation. The association between an early platelet concentrate 
and the need for more blood products postoperatively could be explained by a lowering of the 
transfusion threshold once one transfusion has been administered. An early platelet transfusion 
was not associated with reinterventions, thromboembolic complications, infections, organ failure, 
or mortality. So although platelet concentrates are a relative safe therapy in patients undergoing 
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Thoraxchirugie is een van de snelst ontwikkelende specialismen binnen de geneeskunde. Met 
het ouder worden van de populatie zullen er steeds meer oudere patiënten met bijbehorende 
co- morbiditeit geaccepteerd worden voor een cardio-chirurgische ingreep. Een adequate 
peroperatieve risico inschatting is dan ook onontbeerlijk. Jarenlang werd het EuroSCORE I model 
hiervoor gebruikt, maar met het verstrijken van de tijd daalde de voorspellende waarde van dit 
model. Een opvolger van dit model, de EuroSCORE II werd hierom opgesteld.
In dit proefschrift valideren wij dit nieuwe EuroSCORE model in een Nederlandse populatie en 
onze resultaten laten zien dat het EuroSCORE II model het beter doet dan zijn voorganger. Echter, 
in de patiënten die spoed chirurgie ondergingen of patiënten die een zeer verhoogd preoperatief 
risico liepen vonden wij dat beiden modellen niet adequaat genoeg waren in het voorspellen van 
postoperatieve mortaliteit. Voor deze patiënten zal een nieuw model gecreëerd moeten worden. 
Voor de overige patiënten geldt dat preoperatieve risico inschatting het best gebeurt middels de 
EuroSCORE II.
In de afgelopen decennia werd er gepleit voor een meer restrictief beleid rondom erytrocyten 
transfusie, om zo de blootstelling aan eventuele bijwerkingen van bloedtransfusies te 
minimaliseren. Maar wat een acceptabele grens is voor een minimum Hb waarde is niet bekend 
en het is waarschijnlijk dat dit per patiënt verschilt. Een eerdere studie in cardio-chirurgische 
patiënten heeft het effect van een intra-operatieve Hb daling van vijftig procent of meer 
geanalyseerd en vond dat postoperatieve uitkomsten zoals acuut nierfalen, myocard infarct 
en mortaliteit meer voorkwamen in deze groep. De resultaten van deze studie waren nog niet 
bevestigd of verworpen.
Wij hebben een studie gedaan met een vergelijkbare studieopzet welke liet zien dat patiënten 
die een intra-operatieve Hb daling van meer dan 50 procent doormaken vaker een slechtere 
postoperatieve uitkomst hebben, zelfs als ze boven de veelgebruikte transfusiegrens van 7 g/dL 
blijven, in vergelijking met patiënten die een kleinere Hb daling hebben. Onze resultaten laten 
zien dat het bevorderlijk kan zijn voor de patiënt als men de grootte van de intra-operatieve Hb 
daling meeneemt als men een beslissing moet nemen om wel of niet te transfunderen, zo kan 
men een meer persoonlijke transfusie grens vaststellen.
Een van de moeilijkst te beantwoorden vragen binnen de transfusie geneeskunde is wanneer 
een erytrocyten transfusie meer voordeel oplevert voor de patiënt dan dat hij/zij hinder heeft van 
eventuele bijwerkingen. Het geïsoleerd bestuderen van de effecten van intra-operatieve anemie 
is bijna onmogelijk omdat de behandeling voor anemie bestaat uit erytrocyten transfusies en de 
bijwerkingen van erytrocyten transfusies weer erg kunnen lijken op de effecten van een anemie. 
We hebben geprobeerd dit probleem te omzeilen door intra-operatieve anemie te bestuderen 
in Jehova’s getuigen, die geen bloedproducten gebruiken, en hebben deze Jehova’s getuigen 
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vergeleken met gematchte patiënten die 1 erytrocyten transfusie kregen. Er was geen verschil in 
postoperatieve uitkomst. Dit impliceert dat de erytrocyten transfusie misschien wel achterwege 
had kunnen blijven. Als alle patiënten die cardiochirurgie ondergaan dezelfde pre- en intra-
operatieve behandeling zouden krijgen als Jehova’s getuigen zou dit voor meer transfusies 
kunnen gelden.
Een van de bijwerkingen van een erytrocyten transfusie is de vorming van allo-antilichamen. De 
consequenties van allo-antilichamen varieert van logistieke problemen om compatibel bloed te 
verkrijgen tot acute en late transfusiereacties. Waarom de ene patiënt wel en de andere patiënt 
geen allo-antilichamen vormt na een incompatibele bloedtransfusies is onbekend. Als mogelijke 
factor die bijdraagt aan de vorming van allo-antilichamen wordt de opslagduur van erytrocyten 
genoemd, zoals eerder werd aangetoond in een muis model. De hypothese hierachter is dat 
‘ouder’ bloed meer immunogeen zou zijn en zo dus zou bijdragen aan de vorming van allo-
antilichamen.
Om te onderzoeken of dit waar is hebben we een studie gedaan waarin we de incidentie van anti-K 
vorming hebben geanalyseerd in patiënten die een incompatibele erytrocyten transfusie hebben 
gekregen en hebben we gekeken naar de opslagduur van deze erytrocyten. We hebben groepen 
gemaakt waarin we ‘oude’ met ‘verse’ incompatibele transfusies met elkaar hebben vergeleken 
(14, 18 en 21 dagen als afkappunt). Er werd geen associatie gevonden tussen opslagduur en de 
vorming van anti-K, zelfs niet toen we ook de opslagduur van de gelijktijdige K negatieve in de 
analyse betrokken. Onze resultaten doen vermoeden dat de opslagduur van erytrocyten geen rol 
speelt bij het ontstaan van allo-antilichamen. Welke factoren wel een rol spelen en hoe groot hun 
aandeel is zal uitgemaakt moeten worden door toekomstig onderzoek.
Als het om het effect van trombocyten transfusies gaat binnen de cardiochirurgie worden er 
conflicterende resultaten gepubliceerd. Daarom hebben we in het laatste hoofdstuk van dit 
proefschrift het onafhankelijke effect van een intra-operatief gegeven trombocyten concentraat 
geanalyseerd in patiënten die een cardio-chirurgische ingreep moesten ondergaan. Er werd een 
cohort geselecteerd van patiënten die een enkel trombocyten concentraat kregen nadat zij van 
de cardiopulmonale bypass geweaned waren en dit cohort werd vergeleken met een cohort van 
gematchte patiënten die geen trombocyten kregen toegediend. Het matchen gebeurde middels 
1:3 propensity score matching. Onze resultaten lieten zien dat patiënten die een trombocyten 
transfusie kregen minder bloed verloren maar vaker vasoactieve medicatie nodig hadden, langer 
beademd moesten worden en langer op de intensive care moesten verblijven. Ook kregen 
deze patiënten vaker andere bloedproducten postoperatief. In de literatuur wordt beschreven 
dat vasoplegie een mogelijke bijwerking is van trombocyten transfusies. Dit zou kunnen passen 
bij de bevindingen dat patiënten na een trombocyten transfusie meer vasoactieve medicatie 
nodig hebben en langer aan de beademing en op de intensive care liggen. Het feit dat deze 
patiënten postoperatief meer bloedproducten kregen zou uitgelegd kunnen worden door een 
verlaagde drempel bij de behandelend artsen om nogmaals te transfunderen als dit eenmaal al 
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een keer gedaan is. Tevens vonden we dat een trombocyten transfusie niet geassocieerd was 
met re-interventies, trombo-embolische complicaties, infecties, orgaan falen of mortaliteit. Dus 
alhoewel een trombocyten transfusie relatief veilig is mag men nooit de mogelijke bijwerkingen 
uit het oog verliezen.
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Daarnaast wil ik natuurlijk mijn beide promotores, Anneke Brand en Anske van der Bom bedanken 
voor jullie niet aflatende steun en de figuurlijke trap onder de kont wanneer ik die nodig had. Leo 
van de Watering, mijn co-promotor is ook een drijvende kracht achter dit proefschrift geweest. 
Verder wil ik graag Rutger Middelburg en Henk Schonewille bedanken voor hun hulp bij het 
artikel over allo-immunisatie en natuurlijk ook Nardo van der Meer en Peter Rosseel voor hun 
kritische blik en het aanleveren van de data voor de overige artikelen.
Bianca bedankt voor de hulp bij de vormgeving van dit proefschrift en het drukwerk. Ik snap nu 
waarom vele promovendi bij je aankloppen.
Daarnaast moet ik mijn collegae van de afdeling anesthesiologie van het UMCG bedanken 
voor hun support tijdens de afgelopen 4,5 jaar. Een promotie afronden naast je opleiding tot 
anesthesioloog is best een klus en was niet gelukt als ik niet bij tijd en wijlen bij jullie terecht kon 
om te sparren, uit te huilen of een schouder klopje te krijgen.
Als laatste wil ik mijn naasten bedanken en in het bijzonder Marc-Paul Brörens en Elly Hüntgens. 
Zonder jullie was ik niet waar ik nu ben en dit proefschrift was er al helemaal niet geweest zonder 
jullie. De laatste woorden van dit dankwoord wil ik richten tot de belangrijkste man in mijn leven. 
Maarten, jouw onvoorwaardelijke steun heeft mij de moed gegeven om door te gaan als ik het 
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